

Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1

Daniel P. Mould, Cristina Alli, Ulf Bremberg, Sharon Cartic, Allan M. Jordan, Matthis Geitmann, Alba Maiques-Diaz, Alison E McGonagle, Tim C. P. Somerville, Gary J. Spencer, Fabrice Turlais, and Donald J. Ogilvie

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.7b00462 • Publication Date (Web): 11 Sep 2017

Downloaded from <http://pubs.acs.org> on September 12, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 **Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific**
4
5 **Demethylase 1**
6
7
8
9

10 Daniel P. Mould[†], Cristina Alli[‡], Ulf Bremberg[§], Sharon Cartic[‡], Allan M. Jordan^{†,*}, Matthias
11 Geitmann[§], Alba Maiques-Diaz[‡], Alison E. McGonagle[†], Tim C. P. Somervaille[‡], Gary J. Spencer[‡],
12 Fabrice Turlais[‡], and Donald Ogilvie[†]
13
14
15
16

17
18
19
20
21 [†]Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester,
22 Wilmslow Road, Manchester, M20 4BX, UK
23

24
25 [‡]Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of
26 Manchester, Wilmslow Road, Manchester, M20 4BX, UK
27

28
29 [§]Beactica AB, Uppsala Business Park, Virdings allé 2, 75450, Uppsala, SE
30

31 [‡]CRT Discovery Laboratories, Babraham Campus, Babraham, Cambridgeshire, CB22 3AT, UK
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukaemia (AML). Irreversible inhibitors developed from the non-specific inhibitor tranylcyromine have entered clinical trials; however, the development of effective reversible inhibitors has proved more challenging. Herein, we describe our efforts to identify reversible inhibitors of LSD1 from a high throughput screen, and subsequent *in silico* modelling approaches. From a single hit (**12**) validated by biochemical and biophysical assays, we describe our efforts to develop acyclic scaffold-hops from GSK-690 (**1**). A further scaffold modification to a (4-cyanophenyl)glycinamide (e.g. **29a**) led to the development of compound **32**, with a K_d value of 32 nM and an EC_{50} value of 0.67 μ M in a surrogate cellular biomarker assay. Moreover, this derivative does not display the same level of hERG liability as observed with **1** and represents a promising lead for further development.

Introduction

Lysine specific demethylase 1 (LSD1) was the first histone demethylase to be discovered,¹ and has been found to play an important role in normal and malignant cells as a transcriptional repressor.² LSD1 belongs to the FAD-dependent amine oxidase family of demethylases and catalyzes the demethylation of lysine residues of histones,³ specifically H3K4me1/2 and H3K9me1/2.⁴ Aside from this role, it has become clear that LSD1 plays important scaffolding roles as part of the CoREST complex,⁵ especially in controlling the interaction with transcription factors such as growth factor independence (GFI) 1 and 1b.⁶⁻⁷ LSD1 and GFI1 in combination appear to balance the regulation of hematopoietic cell proliferation and differentiation in hematopoietic stem and progenitor cells.⁸ GFI1 interacts with LSD1 through binding of its C-terminal SNAG domain in the active site of LSD1, suggesting that LSD1 inhibitors may induce their phenotype through abrogation of this protein-protein interaction, and the downstream changes in gene expression this effects, rather than by inhibition of histone demethylation.⁹ In addition, it has been established that LSD1 plays a key role in acute myeloid leukaemia (AML) driven by mixed lineage leukaemia (MLL) fusions,¹⁰ whereby overexpression of LSD1 maintains malignant stem and progenitor cells in a self-renewing state. This has helped to establish a novel treatment hypothesis in a hematological malignancy where the standard of care has changed little in the past three decades.¹¹

There is also evidence that LSD1 inhibition could have a beneficial effect in a number of other disease areas. It has been shown that small cell lung cancer cell lines have high levels of LSD1 overexpression in almost all cases, and some show sensitivity to LSD1 inhibition *in vitro* and in tumour xenografts.¹² The authors suggest a correlation between response and DNA hypomethylation. The consequence of inhibition is similar to AML, in that cells show a differentiation phenotype towards their original neuroendocrine state. LSD1 inhibition has also shown promise for the treatment of herpes simplex infection,^{13, 14} memory deficit,¹⁵ and patents have been filed describing the potential use of LSD1 inhibitors in diseases associated with alterations in protein conformation, such as Alzheimer's, Parkinson's and Huntingdon's diseases.^{16, 17} Irreversible inhibitors of LSD1 developed from the clinical monoamine oxidase (MAO) inhibitor tranylcypromine entered clinical trials in 2014.

1
2
3 These inhibitors will provide valuable insights into the validation of targeting malignant stem and
4 progenitor cells in AML patients. Preliminary clinical trials data of *rel*-N¹-[(1R,2S)-2-
5 phenylcyclopropyl]-1,4-cyclohexanediamine (ORY-1001, Oryzon Genomics) has demonstrated
6 promotion of blast cell differentiation in roughly two-thirds of patients in an extension cohort with
7 specific subtypes of relapsed or refractory AML, although adverse effects limited the maximum
8 tolerated dose.¹⁸ Additional clinical trials are underway with tranlycypromine derivatives from
9 GlaxoSmithKline (Clinicaltrials.gov identifier NCT02177812),¹⁹ and Incyte Corporation
10 (Clinicaltrials.gov identifier NCT02712905),²⁰ although no results have yet been disclosed. The
11 clinical efficacy of LSD1 inhibitors may ultimately be enhanced by way of combination therapies. For
12 example, all-trans-retinoic acid (ATRA) therapy is already successfully used as a differentiation
13 therapy in acute promyelocytic leukaemia (APL), and research has suggested addition of an LSD1
14 inhibitor could enable this therapy to be more widely applicable to AML.²¹ Emerging data suggests
15 the wider applicability of this strategy to other epigenetic targets such as bromodomains,²² and histone
16 deacetylases.²³

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 The development of reversible LSD1 inhibitors is not trivial, due to the large size and polarity of the
33 LSD1 substrate binding pocket. As such, progress has not matched that of the covalent inactivators of
34 LSD1.²⁴ Reversible inhibitors such as GSK-690 (**1**, Figure 1) have achieved good potency in
35 biochemical and cellular assays,²⁵ however this compound strongly inhibits the human ether-a-go-go-
36 related gene (hERG) cardiac ion channel, which prevented the progression of this series to the clinic.²⁶
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148




Figure 1. Compound 1 and examples from several series disclosed by Quanticel Pharmaceuticals(2–6).²⁸


Herein, we describe our efforts towards the development of reversible inhibitors of LSD1 identified by high-throughput screening, and using *in silico* design to develop sub-micromolar inhibitors of LSD1 that show activity in cellular assays.

Chemistry

Aniline 9 (Scheme 1) was prepared from nitrobenzene 7 via aromatic nucleophilic substitution with 3,5-dimethylpyrazole to afford 8, which was reduced with zinc metal and ammonium formate. Aniline 9 was reacted with the requisite sulfonyl chloride in pyridine to afford compounds 10a–b. As described in Scheme 2, compound 12 was formed by the reaction of aniline 11 with 4-acetamidobenzenesulfonyl chloride. Compound 11 was also reacted with 4-methylphenylsulfonyl chloride in acetonitrile in the presence of pyridine to afford sulfonamide 13. Compound 13 was alkylated with tert-butyl bromoacetate to afford the ester 14. Deprotection with trifluoroacetic acid afforded acid 15 as a key intermediate.³⁶ This was reacted with a variety of di-amines under standard amide coupling conditions, with a Boc-deprotection step using 4M HCl/dioxane if required, to give amides 16a–m. Sulfonamides 18–20 were formed under standard conditions, then alkylated with a Boc-protected chloroacetyl piperidine derivative (see Supporting Information for synthesis) to afford derivatives 21–23 (Scheme 3). To synthesize the methylene replacement analogues (Scheme 4),


commercially available (4-cyanophenyl)glycine was reacted with a variety of Boc-protected substituted piperidines under standard amide coupling conditions to afford intermediates **25–28**. Alkylation with a variety of substituted benzyl bromides in DMF in the presence of potassium carbonate, and subsequent Boc-deprotection, afforded compounds **29a–e**, **30a–f**, **31** and **32**.

Scheme 1: Synthesis of compounds **10a–b**^a




^aReagents and conditions: (i) 3,5-dimethylpyrazole, K_2CO_3 , DMF, 80 °C, 16 h, 99%; (ii) Zn, ammonium formate, MeOH, 40 °C, 16 h, 78%; (iii) appropriate sulfonyl chloride, pyridine, 100 °C, 1 h, 41–70%.


Scheme 2: Synthesis of compounds **12** and **16a–m**^a



^aReagents and conditions: (i) 4-acetamidobenzenesulfonyl chloride, DMAP, MeCN, μ W, 100 °C, 1 h, 37%; (ii) 4-methylphenylsulfonyl, pyridine, MeCN, RT, 12 h, 89%; (iii) tert-butyl bromoacetate, K_2CO_3 , DMF, 1 h, 96%; (iv) TFA, DCM, 1 h, 98%; (v) amine, DIPEA, COMU, DMF, then 4M HCl/dioxane if Boc deprotection required, RT, 12–68%.

Scheme 3: Synthesis of compounds 21a–b, 22 and 23^a

^aReagents and conditions: (i) 1-acetylpiperidine-5-sulfonyl chloride, pyridine, MeCN, RT, 12 h, 84%; (ii) **(21a)** *tert*-butyl *N*-[(3*R*)-1-(2-chloroacetyl)-3-piperidyl]carbamate, K₂CO₃, cat. KI, DMF, 80 °C, 3 h; then TFA, 1 h, rt, 42%; **(21b)** *tert*-butyl *N*-[1-(2-chloroacetyl)-4-piperidyl]carbamate, K₂CO₃, 80 °C, 6 h, then 4M HCl/dioxane, 70%; (iii) 2-methyl-2*H*-indazol-5-amine, pyridine, MeCN, rt, 12 h, 54%; (iv) *tert*-butyl *N*-[(3*R*)-1-(2-chloroacetyl)-3-piperidyl]carbamate, K₂CO₃, cat. KI, DMF, 80 °C, 3 h; then TFA, 1 h, rt, 25%; (v) 1-acetylpiperidine-5-sulfonyl chloride, pyridine, MeCN, RT, 12 h, 54%; (vi) *tert*-butyl *N*-[1-(2-chloroacetyl)-4-piperidyl]carbamate, K₂CO₃, DMF, 80 °C, 6 h, then 4M HCl/dioxane, 1 h RT, 52%.

Scheme 4: Synthesis of compounds 29a–e, 30a–f, 31 and 32^a

^aReagents and conditions: i) Boc-protected diamine, DIPEA, COMU, DMF, rt, 1 h, 67 – 99%; ii) substituted benzyl-bromide, K₂CO₃, DMF, 80°C, 1 h, then 4 M HCl/dioxane, rt, 1 h, 6–58%

Results and Discussion

A library of ~150,000 compounds was screened against the LSD1 enzyme in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay at 30 μ M, with an initial hit rate of 0.3% (as defined by >70% inhibition). The resulting 472 compounds were tested for interference of the TR-FRET assay and for purity by LC-MS, then taken into 7- and 12- point IC₅₀ testing, yielding 72 hits with IC₅₀ values in the range of 4–102 μ M.

After resynthesis of the original hit matter for validation, we chose to develop a series of sulfonamides that appeared to offer an attractive start-point with multiple vectors for diversification (Figure 2). This series was optimized from compound **10a** to give **10b** with sub-micromolar activity in the biochemical assay. Both sides of the sulfonamide could be extensively modified while retaining potency; however the aniline portion originating from the HTS could not be improved upon. Unfortunately, when tested in our previously described cellular assay,³⁷ **10b** and related compounds

1
2
3 were found to cause no induction of CD86 at 50 μM in human THP-1 AML cells (Figure 2B). This
4 disconnect was reinforced when the compounds were tested by surface plasmon resonance (SPR),
5 where the binding response increased linearly with compound concentration (Figure 2C, inset),
6 suggesting that no specific binding between compound and LSD1 protein was occurring. In addition,
7 a competition assay with tranilcypromine demonstrated no abrogation of the interactions of these
8 compounds with LSD1 (data not shown). Several other chemotypes emerging from the HTS were
9 shown to display a similar lack of activity by SPR, suggesting the biochemical assay may be
10 particularly susceptible to false positives, and demonstrating the value of an orthogonal biophysical
11 assay in the screening cascade.
12
13
14
15
16
17
18
19
20
21
22




Figure 2. Development and characterization of compound **10b**. A: Biochemical assay; B: Surrogate cellular biomarker assay; C: Surface plasmon resonance sensorgram of the interaction between LSD1 and **10b** in two-fold dilution series (highest concentration indicated in the graph).




Figure 3. Structure of compound **12** with biochemical and SPR sensorgram indicating the highest tested concentration. $K_d = 9.5 \mu\text{M}$. K_d value was determined by SPR at 15 °C as the average of two experimental series (typically 10 concentrations).

SPR analysis did identify a single compound (**12**) that displayed reversible binding activity (Figure 3), a sulfonamide that we hypothesized might be acting as a ring-opened isostere of the pyridine scaffold of compound **1**. While **1** was disclosed by GSK at the AACR Annual Meeting 2013 (Washington DC, USA), very little work to develop this ligand had been published before 2015.³⁸ Certainly, the scope for potential core-hops had been seldom explored at the point at which we began to pursue this approach. To attempt to validate sulfonamides as a potential new scaffold, we used Cresset Spark and Torch software (Welwyn Garden City, U.K.) to align and identify potential new cores by searching fragment libraries for replacements with similar spatial and electronic features.³⁹







Figure 4. Cresset Torch alignment and structures of compound **1** (left) and **16g** (right). Similarity score 0.712. Blue field points (spheres) highlight energy minima for a positively charged probe, red for a negative probe. Yellow spheres represent an attractive van der Waals minimum for a neutral probe and brown spheres represent hydrophobic regions. Oxygen atoms are shown in red, nitrogen in blue. The similarity score is based on the likeness of the field points in terms of their magnitude and position. A score of greater than 0.7 is considered a ‘good’ score.

From this output we designed initial targets, a series of sulfonamidoacetamides (Figure 4) that looked to offer ease of synthesis while offering low two-dimensional (2D) similarity in comparison to more recognizable pyridine replacements such as pyridazines or pyrazines. We incorporated the *para*-cyano and *para*-tolyl aryl groups from **1** for the initial development, focused on optimizing the basic center, by coupling a series of amines to a key sulfonamidoacetic acid intermediate to give compounds **16a–m**. (Table 1). In contrast to the sulfonamides **10a–b**, these compounds showed specific and reversible binding to LSD1 by SPR, validating them as start points for further assay. Both primary and secondary amides decorated with basic amines were tolerated and displayed significantly improved levels of potency over **16a**. Initial optimization gave the 4-aminopiperidine derivative **16g**. Methylation α - to the basic center (**16k**) was also tolerated, alongside methylation on the nitrogen itself (**16l**, **16m**), however the activity appeared have reached a plateau, with no compounds achieving a K_d value below 2 μ M.

Table 1. Optimization of basic center on the acetamididosulfonamide scaffold^a


| Compound | R | IC ₅₀ (μM) | SPR K _d (μM) |
|------------|---|-----------------------|-------------------------|
| 1 | - | 0.037 (0.012) | 0.009 |
| 16a | | >150 | 90 |
| 16b | | 11.9 (0.2) | 3.6 |
| 16c | | 14.2 (0.3) | 3.5 |
| 16d | | 13.1 (0.2) | 2.4 |
| 16e | | 13.9 (0.1) | 4.5 |
| 16f | | 24.3 (0.4) | 10.3 |
| 16g | | 7.6 (1.2) | 2.6 |
| 16h | | 15.6 (1.3) | 6.5 |
| 16i | | 22.7 (1.6) | 4.7 |
| 16j | | 16.4 (0.6) | 3.2 |
| 16k | | 5.2 (0.7) | 2.5 |













| | | | | |
|----|------------|---|------------|-----|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | 16l |  | 7.5 (1.2) | 2.9 |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | 16m |  | 12.6 (1.8) | 2.9 |
| 9 | | | | |
| 10 | | | | |

^aIC₅₀ and K_d values for selected compounds against the LSD1 enzyme in biochemical and biophysical assays. Standard deviation is given in parentheses. IC₅₀ determined from 10 point concentration/effect experiments. Geometric mean of at least two independent experimental determinations given. K_d values were determined by SPR at 15 °C as the average of two experimental series (typically 10 concentrations).

Shortly after synthesizing these initial compounds, a patent from Quantice disclosed several series of reversible LSD1 inhibitors featuring 6- and 5-membered monocyclic and 6,5-bicyclic core-hops (Figure 1).²⁸ Compounds from each series were claimed to display IC₅₀ values against LSD1 of less than 100 nM in biochemical and cellular assays. While the patent reduced the diversity of chemical space available to explore, it also provided useful learning, both in terms of the essential features of the compounds, and which positions are more tolerant to change. For instance, the *para*-cyanophenyl and the presence of a basic nitrogen center are conserved throughout the examples in the patent, whereas the tolyl moiety was more amenable to optimization, and was successfully replaced with a number of mono- and bicyclic systems (e.g. **3**, Figure 1).

Table 2. Aryl modifications on the acetamidulosulfonamide scaffold^a



| Compound | R ¹ | R ² | R ³ | IC ₅₀ (μM) | SPR K _d (μM) |
|------------|---|---|--|--------------------------|----------------------------|
| 1 | - | - | - | 0.037 (0.012) | 0.009 |
| 21a |  |  |  | 5.2 (0.4) | 2.4 |
| 21b |  |  |  | 4.4 (1.0) | 1.8 |
| 22 |  |  |  | 30.0 (2.4) | 9.6 |
| 23 |  |  |  | >30 | >100 |

^aIC₅₀ and K_d values for selected compounds against the LSD1 enzyme in biochemical and biophysical assays. Standard deviation is given in parentheses. IC₅₀ determined from 10-point concentration/effect experiments. Geometric mean of at least two independent experimental determinations given. K_d values were determined by SPR at 15 °C as the average of two experimental series (typically 10 concentrations).

With this in mind, we investigated how the modification of the two aryl groups affected the activity (Table 2). Derivatives with an acetylindoline group were shown to give slightly better potency than the parent tolyl (**21a–b**). On the other hand, compound **22**, where the sulfonamide was reversed and


1
2
3 the tolyl replaced with the favored 2-methylindazole from the Quantice patent, showed a
4
5 disappointing drop-off in activity. Adopting the substituted aniline group from the prior HTS series
6
7 (**23**) showed no activity by biochemical assay or SPR, while the parent **20** (biochemical $IC_{50} = 1.6$
8
9 μM ; $K_d > 100 \mu\text{M}$) displayed the same non-specific binding effects by SPR. Despite our optimization
10
11 attempts, we were disappointed to find that potency could not be significantly improved further, and
12
13 thus we looked to modify the core itself to establish whether potency could be improved..

14
15
16 Toward this aim, we replaced the SO_2 moiety with a methylene linker to give a 4-
17
18 cyanophenylglycinamide core. This alteration has the benefit of a significant reduction in molecular
19
20 weight and total polar surface area, which could afford increased membrane permeability and
21
22 bioavailability. However, this modification also introduces an aniline functionality that could
23
24 potentially be a metabolic liability.⁴⁰ Initially, we chose to adopt the 4-aminopiperidine from
25
26 compound **16g** as the basic center, and focused on modifications of the tolyl- group. Compound **29a**
27
28 demonstrated a 5-fold improvement in potency compared to the matched-pair sulfonamide **16h** by
29
30 both biochemical assay and SPR. In addition, a range of phenyl groups were tolerated and, in one
31
32 case, improved potency further (**29c**). These beneficial modifications could be extended to bicyclic
33
34 systems (**15e**). We then returned to investigate the basic center and found that homologating the 4-
35
36 aminopiperidine unit to a piperidin-4-ylmethanamine gave a useful ~4-fold increase in potency (e.g.
37
38 **29a** vs. **30a**). Modifying the pKa of the basic center by introducing of a fluorine atom at the β -carbon
39
40 to the amine was deleterious to activity, however decreasing the flexibility of the amine by
41
42 incorporation into a spirocycle (**32**) afforded a compound with $<100 \text{ nM}$ activity in the biochemical
43
44 assay.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Aryl optimization on the (4-cyanophenyl)glycine scaffold^a

| Compound | R | IC ₅₀ (μM) | SPR K _d (μM) |
|------------|---|-----------------------|-------------------------|
| 1 | - | 0.037 (0.012) | 0.009 |
| 29a | | 1.3 (0.02) | 0.43 |
| 29b | | 5.5 (0.07) | 1.9 |
| 29c | | 0.81 (0.02) | 0.19 |
| 29d | | 4.1 (0.1) | 1.1 |
| 29e | | 0.62 (0) | 0.14 |

^aIC₅₀ and K_d values for selected compounds against the LSD1 enzyme in biochemical and biophysical assays. Standard deviation is given in parentheses. IC₅₀ determined from 10 point concentration/effect experiments. Geometric mean of at least two independent experimental determinations given. K_d values were determined by SPR at 15 °C as the average of two experimental series (typically 10 concentrations).

Table 4. Basic center optimization and aryl variation on the (4-cyanophenyl)glycine scaffold^a

| Compound | R ¹ | R ² | IC ₅₀ (μM) | SPR K _d (μM) |
|------------|----------------|----------------|-----------------------|-------------------------|
| 1 | - | - | 0.037 (0.012) | 0.009 |
| 30a | | | 0.29 (0.03) | 0.11 |
| 30b | | | 0.40 (0.11) | 0.29 |
| 30c | | | 1.3 (0.15) | 0.46 |
| 30d | | | 1.0 (0.14) | 0.42 |
| 30e | | | 0.83 (0.08) | 0.49 |
| 30f | | | 0.21 (0.06) | 0.058 |
| 31 | | | 0.99 (0.23) | 0.23 |
| 32 | | | 0.083 (0.003) | 0.032 |

^aIC₅₀ and K_d values for selected compounds against the LSD1 enzyme in biochemical and biophysical assays. Standard deviation is given in parentheses. IC₅₀ determined from 10 point concentration/effect experiments. Geometric mean of at least two independent experimental determinations given. K_d values were determined by SPR at 15 °C as the average of two experimental series (typically 10 concentrations).

1
2
3
4
5
6 In an attempt to rationalize the observed SAR, we performed docking studies, using the previously
7 reported structure of LSD1 bound to tetrahydrofolate (PDB accession code 4KUM).⁴¹ Protein
8 preparation and docking were performed in Glide (Schrödinger, New York, USA).⁴² The crystal
9 structure of **1** bound to LSD1 has been disclosed,²⁶ and from these data, the binding mode of
10 compound **30f** was predicted, as displayed in Figure 5. In this predicted pose, the nitrile forms a key
11 hydrogen bonding interaction with K661. The basic center forms a network of ionic interactions with
12 Asp555 and Asp556. This ionic interaction has been exploited previously by Vianello and co-
13 workers.³³⁻³⁴ The 3-fluoro-4-methoxyphenyl group sits in a channel formed by Trp695, Ile356,
14 Leu677 and Leu693. The ether oxygen is predicted to make a hydrogen bonding interaction with
15 Gln358, however, if the phenyl group were to flip then it could also potentially form a similar
16 interaction with Asn535. It is worthy of note that a wide variety of scaffold-hops can be tolerated, and
17 this may be explained by a lack of contact between the protein and the scaffold itself, with the key
18 interactions being located at distal ends of the ligands.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Left: Predicted binding mode of compound **30f** in the LSD1 active site (4KUM). Visualized using Maestro. Right: Protein-ligand interaction diagram with key hydrogen bond interactions highlighted (pink arrows).

To assess the effects of these derivatives on cells, compounds **1**, **30f** and **32** were tested at 7 concentrations in the THP-1 AML cell line to measure their effect on expression levels of CD86, a surrogate cellular biomarker of LSD1 inhibition (Figure 6).³⁷ Although compound **1** displayed the highest levels of potency in this assay ($EC_{50} = 0.30 \mu\text{M}$), we were satisfied to find only a 2-fold drop off in activity to our most active derivative, **32** ($EC_{50} = 0.67 \mu\text{M}$). The less active analogue **30f** displayed more modest activity ($EC_{50} = 4.1 \mu\text{M}$), suggesting good correlation between the biochemical and cellular assay.




Figure 6. CD86 cell assay results for compounds **1**, **30f** and **32**.

To further assess cellular effects, we performed colony forming assays using two AML cell lines. This assay format indicates both proliferation of a cell population and the percentage of cells within that population with colony initiating activity.¹⁰ THP1, and MV4-11 cells were treated with 10 μM of **1** or **32** for 7 days in semi-solid methylcellulose-based culture. Both compounds substantially reduced both colony forming frequency and the size of the colonies that did develop (Figure 7) indicating significant anti-proliferative activity, in addition to inducing up-regulation of the cellular differentiation marker CD86. To explore whether these compounds induced apoptosis, we performed

Annexin V-perCP EF710/7AAD staining on THP-1 cells treated for four days with 10 μ M of each of the compounds. A modest but significant increase in apoptosis was observed (Figure 8). These results, combined with the CD86 data, suggest that compounds such as **32** act predominantly to promote differentiation of AML cells, with concomitant reduction in clonogenic potential.





Figure 7. Top: Colony formation assay for THP-1 and MV4-11 cells dosed with 10 μ M of compounds **1** and **32** for 7 days. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, statistical significance calculated using a one-way ANOVA with Dunnett's tests between vehicle treated and compound dosed cells. Bottom: representative images of colonies.




Figure 8. Annexin V-perCP EF710/7AAD double staining experiments results with THP-1 cell dosed with vehicle, or 10 μ M **1** or **32** for 4 days in liquid culture. Early apoptotic cells = Annexin V^{pos}7-AAD^{neg}; Apoptotic cells = Annexin V^{pos}7-AAD^{pos}. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, statistical significance calculated using one-way ANOVA analysis with Dunnett's tests.

in vitro ADME properties

As inhibition of the hERG ion channel proved to be an insurmountable issue in furthering the development of **1** towards the clinic,²⁶ we were keen to assess our compounds against this target. Compounds **29c**, **30f**, and **32** were tested in a patch clamp assay, alongside being profiled for their metabolic stability (Table 5). Gratifyingly these compounds displayed improved selectivity against hERG in comparison to **1** ($IC_{50} = 3.2 \mu$ M), with compound **32** displaying a ~30-fold window of selectivity between LSD1 inhibition in cells and hERG inhibition. In addition, we observed low levels of clearance in mouse microsomes with all three compounds. Disappointingly, these compounds displayed poor membrane permeability and high levels of efflux in comparison to compound **1**, which

could make achieving oral bioavailability challenging, although this liability does not appear to preclude the ability of the compounds to inhibit LSD1 in a cellular context.

Table 5. In vitro parameters for 1, 29c, 30f and 32

| | 1 | 29c | 30f | 32 |
|--|-----------|------------|------------|------------|
| Caco2 A–B mean P_{app} (10^{-6} cm/s); (efflux ratio) | 5.6 (3.2) | 0.44 (48) | 0.26 (58) | 0.09 (58) |
| Mo Mic CL_{int} ($\mu\text{L}/\text{min}/10^6$ cells) | 3.43 | 3.6 | 4.5 | <1 |
| Mo Mic $T_{1/2}$ (min) | 404 | 385 | 305 | >1000 |
| hERG EC_{50} (μM); (standard error) | 3.2 | >25 | 12.4 (3.4) | 20.1 (4.6) |

CONCLUSION

In conclusion, we have developed a series of (4-cyanophenyl)glycine derivatives that show potent activity against LSD1 by both biochemical assay and SPR. Starting from a weakly active HTS hit **12**, we identified acyclic lead-like analogues of compound **1**. We successfully developed these initial start points, leading to the development of compound **32**, which potently inhibits LSD1 in biochemical, biophysical and cellular assays. These compounds display much greater levels of selectivity over the hERG cardiac ion channel than compound **1**, a liability which precluded further development of that series. Compound **32** is an attractive tool compound for use in in vitro systems and start-point for future development. More generally, this work suggests the scaffold of compound **1** is broadly modifiable, and while the *p*-cyanophenyl group appears to form a key interaction with K661, modification of the tolyl- functionality and the position and orientation of basic center is much more tolerant to modification.

Experimental Section

Chemistry

1
2
3 Flash column chromatography was performed using pre-packed silica gel cartridges (KP-Sil SNAP,
4 Biotage, Hengoed UK or RediSep Rf, Isco). Thin layer chromatography was conducted with 5 × 10
5 cm plates coated with Merck Type 60 F₂₅₄ silica gel to a thickness of 0.25 mm. All reagents obtained
6
7
8
9 from commercial sources were used without further purification. Anhydrous solvents were obtained
10
11 from the Sigma-Aldrich Company Ltd. (Dorset, UK) or Fisher Scientific UK Ltd. (Loughborough,
12
13 UK), and used without further drying. HPLC grade solvents were obtained from Fisher Chemicals
14
15 Ltd.

16
17
18 All compounds prepared were >95% purity as determined by examination of both the LC-MS and ¹H
19
20 NMR spectra unless otherwise indicated. Where Cl or Br were present, expected isotopic distribution
21
22 patterns were observed.

23
24
25 Proton (¹H) and carbon (¹³C) NMR spectra were recorded on a 300 MHz Bruker Avance
26
27 spectrometer. Solutions were typically prepared in either deuteriochloroform (CDCl₃), deuterated
28
29 dimethylsulfoxide (DMSO-*d*₆) or deuterated methanol (methanol-*d*₄) with chemical shifts referenced
30
31 to tetramethylsilane (TMS) or deuterated solvent as an internal standard. ¹H NMR data are reported
32
33 indicating the chemical shift (δ), the integration (e.g. 1H), the multiplicity (s, singlet; d, doublet; t,
34
35 triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublets etc.), and the coupling constant (*J*)
36
37 in Hz. Deuterated solvents were obtained from Goss Scientific (Crewe, UK). In general, basic N-H
38
39 protons were not observed.

40
41
42 LC-MS analyses were performed on a Waters (Elstree, UK) Acquity UPLC system fitted with BEH
43
44 C18 1.7 μ M columns (2.1 × 50 mm) and with UV diode array detection (210–400 nm) with a Waters
45
46 SQD detector. Analyses were performed with either buffered acidic or basic solvents, and using
47
48 gradients detailed in the Supporting Information.

49
50
51 Some compounds were purified by preparative (prep.) HPLC on a Waters FractionLynx MS
52
53 autopurification system, with a Waters XBridge 5 μ m C18, 100 mm × 19 mm i.d. column, running at
54
55 a flow rate of 20 mL/min with UV diode array detection (210–400 nm) and mass-directed collection
56
57 using both positive and negative mass ion detection. Purifications were performed using buffered
58
59
60

1
2
3 acidic or basic solvent systems as appropriate. Compound retention times on the system were
4
5 routinely assessed using a 30–50 μL test injection and a standard gradient, then purified using an
6
7 appropriately chosen focused gradient as detailed in the Supporting Information, based upon observed
8
9 retention time.

10 11 **Preparation of compounds 10a–b**

12 13 **1-(2-Methoxy-4-nitro-phenyl)-3,5-dimethylpyrazole (8).**

14
15
16 A suspension of 3-methoxy-4-fluoronitrobenzene (25 g, 146 mmol), 3,5-dimethylpyrazole (15.5 g,
17
18 161 mmol) and potassium carbonate (60.5 g, 438 mmol) in DMF (200 mL) was stirred overnight at 80
19
20 $^{\circ}\text{C}$. The reaction mixture was added to water (500 mL) and the resulting yellow precipitate collected
21
22 by filtration and dried to the title compound (35.8 g, 99%) as a yellow powder. ^1H NMR (300 MHz,
23
24 Chloroform-*d*) δ 7.95 (dd, $J = 8.5, 2.4$ Hz, 1H), 7.90 (d, $J = 2.4$ Hz, 1H), 7.54 (d, $J = 8.5$ Hz, 1H),
25
26 6.03 (s, 1H), 3.94 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H). LC-MS: (High pH) t_{R} 1.09 min, m/z 248.1
27
28 $[\text{M}+\text{H}]^+$, 100% purity.

29 30 31 **4-(3,5-Dimethylpyrazol-1-yl)-3-methoxyaniline (9).**

32
33
34 A stirred suspension of 1-(2-methoxy-4-nitro-phenyl)-3,5-dimethylpyrazole (36 g, 0.145 mol), zinc
35
36 powder (28.6 g, 0.44 mol) and ammonium formate (91.2 g, 1.46 mol) in methanol (250 mL) was
37
38 heated overnight to 40 $^{\circ}\text{C}$. The reaction mixture was passed through a hydrophobic frit and
39
40 concentrated to dryness. The resulting residue was suspended between brine (250 mL) and DCM (500
41
42 mL), the organic layer passed through a hydrophobic frit and concentrated to dryness to afford the
43
44 crude product. Recrystallization from hexanes afforded the title compound (24.7 g, 78%) as off-white
45
46 needles. ^1H NMR (300 MHz, Chloroform-*d*) δ 7.13–7.03 (m, 1H), 6.36 (m, 2H), 5.94 (s, 1H), 3.74 (s,
47
48 3H), 2.30 (s, 3H), 2.08 (s, 3H). LC-MS: (High pH) t_{R} 0.88 min, m/z 218.2 $[\text{M}+\text{H}]^+$, 98% purity.

49 50 51 ***N*-[4-(3,5-Dimethylpyrazol-1-yl)-3-methoxyphenyl]benzenesulfonamide (10a).**

52
53
54 A solution of benzenesulfonyl chloride (18 μL , 0.14 mmol) and 4-(3,5-dimethylpyrazol-1-yl)-3-
55
56 methoxy-aniline (30 mg, 0.14 mmol) in pyridine (0.45 mL) was stirred at 100 $^{\circ}\text{C}$ for 1 hour. The
57
58
59
60

1
2
3 reaction was concentrated to dryness then purified by preparative HPLC (low pH gradient 3) to afford
4
5 the title compound (20 mg, 41%) as a white powder. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.39 (s, 1H),
6
7 7.90–7.75 (m, 2H), 7.65–7.42 (m, 3H), 7.02 (d, $J = 8.4$ Hz, 1H), 6.83 (d, $J = 2.2$ Hz, 1H), 6.67 (dd, J
8
9 = 8.4, 2.2 Hz, 1H), 5.94–5.81 (m, 1H), 3.62 (s, 3H), 2.09 (s, 3H), 1.91 (s, 3H).

10
11
12 ***N*-[4-(3,5-Dimethylpyrazol-1-yl)-3-methoxyphenyl]-1,3-dimethyl-2-oxo-quinoline-6-sulfonamide**
13
14 **(10b).**

15
16 A solution of 4-(3,5-dimethylpyrazol-1-yl)-3-methoxyaniline (28 mg, 0.13 mmol) and 1,3-dimethyl-2-
17
18 oxo-quinoline-6-sulfonyl chloride (34 mg, 0.12 mmol) in pyridine (300 μL) was stirred at room
19
20 temperature overnight. The reaction mixture was diluted with 2:1:1 (v:v:v) DMSO :water:MeCN (700
21
22 μL), then purified by preparative HPLC (low pH) to afford the title compound (39 mg, 70%) as a
23
24 white powder. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 10.62 (s, 1H), 8.15 (d, $J = 2.2$ Hz, 1H), 7.97–7.86
25
26 (m, 2H), 7.67 (d, $J = 9.0$ Hz, 1H), 7.08 (d, $J = 8.4$ Hz, 1H), 6.93 (d, $J = 2.2$ Hz, 1H), 6.75 (dd, $J = 8.4$,
27
28 2.2 Hz, 1H), 5.90 (s, 1H), 3.66 (s, 3H), 3.64 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 1.91 (s, 3H). ^{13}C NMR
29
30 (75 MHz, Methanol- d_4) δ 144.1, 140.5, 137.6, 135.1, 133.2, 130.5, 128.7, 124.8, 122.1, 114.7, 114.0,
31
32 110.8, 106.8, 57.4, 30.9, 22.4, 15.7, 15.2. HRMS (ESI) m/z $[\text{M-H}]^-$ calcd for $\text{C}_{23}\text{H}_{23}\text{N}_4\text{O}_4\text{S}$: 451.1445.
33
34 Found: 451.1443.
35
36
37
38

39 **Preparation of compound 12**

40
41
42 ***N*-[4-[(4-Cyanophenyl)sulfamoyl]phenyl]acetamide (12).**

43
44 A solution of DMAP (50 mg, 0.42mmol), *p*-cyanoaniline (50 mg, 0.42 mmol) and 4-
45
46 acetamidobenzenesulfonyl chloride (99 mg, 0.42 mmol) in acetonitrile (5 mL) was heated by
47
48 microwave irradiation to 100 $^\circ\text{C}$ for 1 h. The reaction was concentrated to dryness then purified by
49
50 preparative HPLC (low pH gradient 2) to afford the title compound (49 mg, 37%) as colourless
51
52 crystals. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 10.95 (s, 1H), 10.34 (s, 1H), 7.83–7.62 (m, 6H), 7.28–7.15
53
54 (m, 2H), 2.06 (s, 3H).
55
56
57

58 **Preparation of compounds 16a–16m**

***N*-(4-Cyanophenyl)-4-methylbenzenesulfonamide (13).**

To a stirred solution of 4-cyanoaniline (5 g, 42.3 mmol) in pyridine (3.6 mL) and acetonitrile (9 mL) was added portionwise *p*-toluenesulfonyl chloride (8.88 g, 46.6 mmol). The reaction mixture was stirred at room temperature overnight, then water (50 mL) was added and the resulting light orange precipitate collected by filtration, washed with water (3 × 20 mL) and dried under vacuum at 50 °C to afford the title compound (8.92 g, 77%) as a light orange powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 7.78–7.61 (m, 4H), 7.43–7.33 (m, 2H), 7.32–7.15 (m, 2H), 2.34 (s, 3H). LC-MS: (High pH) *t*_R 0.82 min, *m/z* 271.1 [M–H][–], 100% purity.

***tert*-Butyl 2-[4-cyano-*N*-(*p*-tolylsulfonyl)anilino]acetate (14).**

To a stirred suspension of *N*-(4-cyanophenyl)-4-methylbenzenesulfonamide (2 g, 7.34 mmol) and potassium carbonate (2.02 g, 14.7 mmol) in DMF (20 mL) was added *tert*-butyl bromoacetate (1.30 mL, 8.81 mmol) and the reaction mixture heated to 80°C for 1 h. The reaction mixture was diluted with water (50 mL) then extracted with DCM (2 × 20 mL). The combined organic layers were passed through a hydrophobic frit and concentrated to dryness to afford the title compound (2.71g, 97%) as an orange oil. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.66–7.51 (m, 4H), 7.41–7.23 (m, 4H), 4.35 (s, 2H), 2.43 (s, 3H), 1.40 (s, 9H). LC-MS: (High pH) *t*_R 1.32 min, *m/z* 387.1 [M+H]⁺, 94% purity.

2-[4-Cyano-*N*-(*p*-tolylsulfonyl)anilino]acetic acid (15).

A stirred solution of *tert*-butyl 2-[4-cyano-*N*-(*p*-tolylsulfonyl)anilino]acetate (2.9 g, 7.5 mmol) in trifluoroacetic acid (2.79 mL, 37.5 mmol) and DCM (30 mL) was heated to 30 °C for 1 h. The reaction mixture was concentrated to dryness to afford an orange oil. Purification by column chromatography (0 to 60% EtOAc in isohexane, then 10% MeOH in DCM) afforded the title compound as a colourless oil that solidified upon standing to give colourless crystals. ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.06 (s, 1H), 7.87–7.75 (m, 2H), 7.65–7.53 (m, 2H), 7.39 (m, 4H), 4.55 (s, 2H), 2.38 (s, 3H). LC-MS: (High pH) *t*_R 0.63 min, *m/z* 319.1 [M–H][–], 96% purity.

1
2
3 **General method A:** To a stirred solution of 2-[4-cyano-*N*-(*p*-tolylsulfonyl)anilino]acetic acid (30.
4 mg, 0.09 mmol), the appropriate bis-amine (1.2 eq.) and *N,N*-Diisopropylethylamine (45 μ L, 0.27
5 mmol) in DMF (300 μ L) was added COMU (58 mg, 0.14 mmol) and the reaction mixture stirred at
6 room temperature for 6 h. The reaction mixture was concentrated to dryness and purified by mass
7 directed preparative HPLC (high pH), to afford the desired product.
8
9

10
11
12
13 **General method B:** To a stirred solution of 2-[4-cyano-*N*-(*p*-tolylsulfonyl)anilino]acetic acid (30 mg,
14 0.09 mmol), the appropriate Boc-protected bis-amine (1.2 eq.) and *N,N*-diisopropylethylamine (45
15 μ L, 0.27 mmol) in DMF (300 μ L) was added COMU (58 mg, 0.14mmol) and the reaction mixture
16 stirred at room temperature for 6 h. The reaction mixture was concentrated to dryness and 4 M HCl in
17 dioxane (1 mL) was added. This was stirred for 1 h, then concentrated to dryness and purified by mass
18 directed preparative HPLC (high pH), to afford the desired product.
19
20
21
22
23
24
25
26

27 **2-[4-Cyano-*N*-(*p*-tolylsulfonyl)anilino]-*N*-(3-pyridyl)acetamide (16a).**

28
29 Prepared by general method A using 3-aminopyridine to afford the title compound (24 mg, 65%) as a
30 light brown powder. $^1\text{H NMR}$ (300 MHz, Methanol- d_4) δ 8.68 (dd, $J = 2.6, 0.8$ Hz, 1H), 8.27 (dd, $J =$
31 4.8, 1.5 Hz, 1H), 8.07 (ddd, $J = 8.4, 2.6, 1.5$ Hz, 1H), 7.72–7.65 (m, 2H), 7.63–7.57 (m, 2H), 7.54–
32 7.43 (m, 2H), 7.44–7.28 (m, 3H), 4.61 (s, 2H), 2.42 (s, 3H).
33
34
35
36
37
38

39 **2-[4-Cyano-*N*-(*p*-tolylsulfonyl)anilino]-*N*-[(3*R*)-quinuclidin-3-yl]acetamide (16b).**

40
41 Prepared by general method A using (*R*)-3-aminoquinuclidine dihydrochloride to afford the title
42 product as an orange oil (14 mg, 35%). $^1\text{H NMR}$ (300 MHz, Methanol- d_4) δ 8.49 (s, 1H), 7.75–7.63
43 (m, 2H), 7.60–7.50 (m, 2H), 7.42 (m, 2H), 7.40–7.34 (m, 2H), 4.42 (s, 2H), 4.17 (m, 1H), 3.74–3.60
44 (m, 1H), 3.34–3.19 (m, 4H), 3.02 (dd, $J = 13.8, 4.7$ Hz, 1H), 2.44 (s, 3H), 2.12 (q, $J = 3.1$ Hz, 1H),
45 1.99 (s, 3H), 1.86 (s, 1H).
46
47
48
49
50
51

52 **2-[4-Cyano-*N*-(*p*-tolylsulfonyl)anilino]-*N*-[(3*S*)-quinuclidin-3-yl]acetamide (16c).**

53
54 Prepared by general method A using (*S*)-3-aminoquinuclidine dihydrochloride to afford the title
55 product as a yellow powder (11 mg, 28%). $^1\text{H NMR}$ (300 MHz, Methanol- d_4) δ 8.46 (s, 1H), 7.70 (dd,
56
57
58
59
60

1
2
3 $J = 1.9, 8.7$ Hz, 2H), 7.60–7.50 (m, 2H), 7.47–7.40 (m, 2H), 7.37 (d, $J = 7.9$ Hz, 2H), 4.43 (s, 2H),
4
5 4.19 (m, 1H), 3.72–3.62 (m, 1H), 3.29–3.22 (m, 3H), 3.04 (dd, $J = 13.8, 4.7$ Hz, 1H), 2.44 (s, 3H),
6
7 2.13 (m, 1H), 2.06–1.97 (m, 4H), 1.87 (s, 1H).
8

9
10 ***N*-(4-Cyanophenyl)-*N*-[2-[(1*S*,4*S*)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-oxo-ethyl]-4-methyl-**
11
12 **benzenesulfonamide (16d).**

13
14 Prepared by general method B using (1*S*,4*S*)-2-Boc-2,5-diazabicyclo[2.2.1]heptane to afford the title
15 compound (28 mg, 75%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.50 (s, 1H), 7.78–
16
17 7.60 (m, 2H), 7.64–7.47 (m, 2H), 7.50–7.25 (m, 4H), 4.43 (s, 2H), 4.18 (ddd, $J = 8.3, 5.3, 3.3$ Hz,
18
19 1H), 3.74–3.59 (m, 1H), 3.34–3.15 (m, 4H), 3.02 (ddd, $J = 13.5, 5.3, 2.2$ Hz, 1H), 2.43 (s, 3H), 2.18–
20
21 1.90 (m, 2H), 1.88–1.76 (m, 1H)
22
23

24
25 ***N*-[2-[(3*R*)-3-Amino-1-piperidyl]-2-oxo-ethyl]-*N*-(4-cyanophenyl)-4-methyl-benzenesulfonamide**
26
27 **(16e).**

28
29 Prepared by general method B using (*R*)-3-Boc-aminopiperidine to afford the title compound (14 mg,
30
31 37%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 6.85–6.78 (m, 2H), 6.78–6.68 (m, 2H),
32
33 6.60–6.53 (m, 2H), 6.51 (d, $J = 8.1$ Hz, 2H), 3.89 (d, $J = 16.5$ Hz, 1H), 3.81 (d, $J = 16.5$ Hz, 1H), 3.38
34
35 (d, $J = 12.5$ Hz, 1H), 3.29–3.08 (m, 1H), 2.96 (d, $J = 13.7$ Hz, 1H), 2.61–2.06 (m, 3H), 1.58 (s, 3H),
36
37 1.08–1.00 (m, 1H), 0.92–0.78 (m, 2H).
38
39

40
41 ***N*-[2-[(3*S*)-3-Amino-1-piperidyl]-2-oxo-ethyl]-*N*-(4-cyanophenyl)-4-methyl-benzenesulfonamide**
42
43 **(16f).**

44
45 Prepared by general method B using (*S*)-3-Boc-aminopiperidine to afford the title compound (18 mg,
46
47 48%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.81–7.74 (m, 2H), 7.72–7.60 (m, 2H),
48
49 7.43–7.27 (m, 4H), 4.85 (d, $J = 17.3$ Hz, 1H), 4.70 (d, $J = 17.3$ Hz, 1H), 4.16–4.04 (m, 1H), 3.71 (d, J
50
51 = 12.5 Hz, 2H), 3.10–2.86 (m, 1H), 2.86 (s, 1H), 2.73–2.51 (m, 1H), 2.38 (s, 3H), 1.95–1.12 (m, 4H).
52
53
54

55
56 ***N*-[2-(4-Amino-1-piperidyl)-2-oxo-ethyl]-*N*-(4-cyanophenyl)-4-methyl-benzenesulfonamide**
57
58 **(16g).**
59
60

1
2
3 Prepared by general method B using 4-[(tert-Butoxycarbonyl)amino]piperidine to afford the title
4 compound (21 mg, 56%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.87–7.69 (m, 2H),
5 7.74–7.59 (m, 2H), 7.43–7.30 (m, 4H), 4.85 (d, *J* = 17.3 Hz, 1H), 4.70 (d, *J* = 17.3 Hz, 1H), 4.18 (d, *J*
6 = 13.7 Hz, 1H), 3.88 (d, *J* = 13.7 Hz, 1H), 3.09 (m, 2H), 2.73–2.53 (m, 1H), 2.38 (s, 3H), 1.85 (m,
7 2H), 1.50–1.30 (m, 1H), 1.31–1.07 (m, 1H).
8
9
10
11
12

13
14 **2-[4-Cyano-*N*-(*p*-tolylsulfonyl)anilino]-*N*-(4-piperidyl)acetamide (16h).**
15

16
17 Prepared by general method B using 4-amino-1-Boc-piperidine to afford the title compound (19 mg,
18 51%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.15 (d, *J* = 7.6 Hz, 1H), 7.90–7.71 (m,
19 2H), 7.62–7.50 (m, 2H), 7.48–7.30 (m, 4H), 4.33 (s, 2H), 3.70–3.53 (m, 2H), 3.11–2.97 (m, 2H),
20 2.75–2.61 (m, 2H), 2.39 (s, 3H), 1.72–1.59 (m, 2H), 1.45–1.27 (m, 2H).
21
22
23
24

25
26 ***N*-[2-[(3*S*)-3-Aminopyrrolidin-1-yl]-2-oxo-ethyl]-*N*-(4-cyanophenyl)-4-methyl-**
27
28 **benzenesulfonamide (16i).**
29

30
31 Prepared by general method B using (*S*)-3-(Boc-amino)pyrrolidine to afford the title compound (18
32 mg, 50%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.84–7.72 (m, 2H), 7.66 (dq, *J* = 8.6,
33 2.2 Hz, 2H), 7.50–7.27 (m, 5H), 4.65 (s, 1H), 4.61 (s, 1H), 3.69–3.48 (m, 1H), 3.47–3.07 (m, 3H),
34 2.38 (s, 3H), 2.13–1.85 (m, 1H), 1.85–1.52 (m, 1H).
35
36
37
38

39
40 ***N*-[2-[(3*R*)-3-Aminopyrrolidin-1-yl]-2-oxo-ethyl]-*N*-(4-cyanophenyl)-4-methyl-**
41
42 **benzenesulfonamide (16j).**
43

44
45 Prepared by general method B using (*R*)-3-(Boc-amino)pyrrolidine to afford the title compound (23
46 mg, 64%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.84–7.72 (m, 2H), 7.72–7.58 (m,
47 2H), 7.42–7.34 (m, 4H), 4.75–4.55 (m, 2H), 3.69–3.56 (m, 1H), 3.62–3.21 (m, 3H), 3.16 (m, 1H),
48 2.38 (s, 3H), 2.13–1.85 (m, 1H), 1.85–1.51 (m, 1H).
49
50
51
52

53
54 ***N*-[2-(4-Amino-4-methyl-1-piperidyl)-2-oxo-ethyl]-*N*-(4-cyanophenyl)-4-methyl-**
55
56 **benzenesulfonamide (16k).**
57
58
59
60

1
2
3 Prepared by general method B using *tert*-butyl *N*-(4-methyl-4-piperidyl)carbamate to afford the title
4
5 compound (26 mg, 67%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.57 (d, 2H), 7.49
6
7 (d, *J* = 8.2 Hz, 2H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 2H), 4.68 (d, *J* = 16.7 Hz, 1H), 4.57
8
9 (d, *J* = 16.7 Hz, 1H), 3.91 (m, 2H), 3.43–3.28 (m, 1H), 3.17–2.97 (m, 1H), 2.33 (s, 3H), 1.81 (s, 2H),
10
11 1.75–1.53 (m, 2H), 1.38 (s, 3H).

12
13
14 ***N*-(4-Cyanophenyl)-4-methyl-*N*-[2-[4-(methylamino)-1-piperidyl]-2-oxo-
15
16 ethyl]benzenesulfonamide (16l).**

17
18 Prepared by general method B using *tert*-butyl *N*-methyl-*N*-(piperidin-4-yl)carbamate to afford the
19
20 title compound (21 mg, 39%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.73–7.64 (m,
21
22 2H), 7.65–7.53 (m, 2H), 7.45–7.39 (m, 2H), 7.39–7.32 (m, 2H), 4.77 (d, *J* = 16.5 Hz, 1H), 4.63 (d, *J* =
23
24 16.5 Hz, 1H), 4.51 (d, *J* = 14.0 Hz, 1H), 4.18 (d, *J* = 14.0 Hz, 1H), 3.31–3.13 (m, 2H), 2.72 (s, 3H),
25
26 2.43 (s, 3H), 2.17 (m, 2H), 1.66 (qd, *J* = 12.3, 4.3 Hz, 1H), 1.43 (qd, *J* = 12.3, 4.3 Hz, 1H).

27
28
29
30 ***N*-(4-Cyanophenyl)-*N*-[2-[4-(dimethylamino)-1-piperidyl]-2-oxo-ethyl]-4-methyl-
31
32 benzenesulfonamide (16m).**

33
34 Prepared by general method A using 4-dimethylaminopiperidine to afford the title compound (26 mg,
35
36 65%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.71–7.63 (m, 2H), 7.63–7.55 (m, 2H),
37
38 7.45–7.39 (m, 2H), 7.39–7.32 (m, 2H), 4.76 (d, *J* = 16.5 Hz, 1H), 4.64 (d, *J* = 16.5 Hz, 1H), 4.56 (d, *J*
39
40 = 14.0 Hz, 1H), 4.20 (d, *J* = 14.0 Hz, 1H), 3.19 (t, *J* = 12.6 Hz, 1H), 2.78 (s, 6H), 2.74–2.59 (m, 1H),
41
42 2.43 (s, 3H), 2.12 (m, 2H), 1.75 (qd, *J* = 12.2, 4.2 Hz, 1H), 1.51 (dd, *J* = 12.2, 4.2 Hz, 1H).

43
44
45
46 **Preparation of compounds 21–27**

47
48 **1-Acetyl-*N*-(4-cyanophenyl)indoline-5-sulfonamide (18).**

49
50 Prepared in a manner analogous to compound **11** to afford the title compound as a light orange
51
52 powder (486 mg, 84%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.95 (s, 1H), 8.11 (d, *J* = 8.4 Hz, 1H),
53
54 7.76–7.61 (m, 4H), 7.29–7.17 (m, 2H), 4.11 (t, *J* = 8.6 Hz, 2H), 3.15 (t, *J* = 8.6 Hz, 2H), 2.15 (s, 3H).
55
56 LC-MS: (High pH) *t*_R 0.76 min, *m/z* 340.1 [M–H][–], 96% purity.
57
58
59
60

4-Cyano-*N*-(2-methylindazol-5-yl)benzenesulfonamide (19).

To a stirred solution of 2-methyl-2*H*-indazol-5-amine (1 g, 6.8 mmol) in pyridine (0.9 mL) and acetonitrile (4 mL) was added 4-cyanobenzenesulfonyl chloride (1.51 g, 7.5 mmol). The reaction mixture was stirred at room temperature overnight, then water (50 mL) was added and the resulting light orange precipitate collected by filtration, washed with water (3 × 20 mL) and dried under vacuum at 50 °C to the title compound (1.15 g, 54%) as a light orange powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.36 (s, 1H), 8.25 (s, 1H), 8.00 (d, *J* = 8.4 Hz, 2H), 7.88–7.82 (m, 2H), 7.82–7.74 (m, 1H), 7.49 (dd, *J* = 9.1, 0.9 Hz, 1H), 7.36 (d, *J* = 2.0 Hz, 1H), 6.98 (dd, *J* = 9.1, 2.0 Hz, 1H), 4.11 (s, 3H). LC-MS: (High pH) *t*_R 0.74 min, *m/z* 311.1 [M–H][–], 100% purity.

1-Acetyl-*N*-[2-[(3*R*)-3-amino-1-piperidyl]-2-oxo-ethyl]-*N*-(4-cyanophenyl)indoline-5-sulfonamide (21a)

A stirred suspension of **18** (30 mg, 0.09 mmol), *tert*-butyl *N*-[(3*R*)-1-(2-chloroacetyl)-3-piperidyl]carbamate (**SI1**, 27 mg, 0.10 mmol), potassium carbonate (18 mg, 0.13 mmol) and potassium iodide (2 mg) in DMF (800 μL) was stirred at 80 °C for 3 hours. The reaction mixture was adsorbed onto silica and concentrated to dryness. Purification by CombiFlash (0 to 30% EtOAc in isohexane) afforded the Boc protected product. This was stirred in TFA (0.5 mL) and DCM (3 mL) then concentrated to dryness to afford the title compound (32 mg, 76%) as a white powder, TFA salt. ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.19 (d, *J* = 8.8 Hz, 1H), 7.76–7.61 (m, 2H), 7.55 (d, *J* = 8.4 Hz, 2H), 7.44 (d, *J* = 8.4 Hz, 2H), 4.79 (d, *J* = 16.5 Hz, 1H), 4.67 (d, *J* = 16.5 Hz, 1H), 4.21 (t, *J* = 8.6 Hz, 2H), 3.93–3.77 (m, 1H), 3.67 (s, 3H), 3.24 (t, *J* = 8.9 Hz, 2H), 2.27 (s, 3H), 2.20–2.09 (m, 1H), 1.99–1.86 (m, 1H), 1.83–1.64 (m, 2H), 1.45 (d, *J* = 10.9 Hz, 1H).

1-Acetyl-*N*-[2-(4-amino-1-piperidyl)-2-oxo-ethyl]-*N*-(4-cyanophenyl)indoline-5-sulfonamide (21b).

A stirred suspension of **18** (50 mg, 0.15 mmol), *tert*-butyl *N*-[1-(2-chloroacetyl)-4-piperidyl]carbamate (**SI2**, 49 mg, 0.18 mmol) and potassium carbonate (40 mg, 0.29 mmol) in DMF (1 mL) was heated to 80 °C for 6 h. EtOAc (5 mL) was added and the reaction mixture filtered

1
2
3 through an Isolute filter cartridge, then concentrated to dryness. 4 M HCl/dioxane (1 mL) was then
4 added. After 1 h the reaction mixture was concentrated to dryness under vacuum, and the resulting
5 residue was purified by preparative HPLC (high pH) to afford the title compound (29 mg, 41%) as a
6 light yellow powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.16 (d, *J* = 8.6 Hz, 1H), 7.71–7.59 (m, 2H),
7 7.53 (d, *J* = 7.8 Hz, 2H), 7.48–7.34 (m, 2H), 4.79 (d, *J* = 16.5 Hz, 1H), 4.65 (d, *J* = 16.5 Hz, 1H), 4.47
8 (d, *J* = 13.8 Hz, 1H), 4.29–4.09 (m, 3H), 3.40 (ddt, *J* = 11.8, 7.4, 4.1 Hz, 1H), 3.26–3.15 (m, 3H), 2.73
9 (td, *J* = 13.3, 12.6, 2.8 Hz, 1H), 2.26 (s, 3H), 2.14 (d, *J* = 12.5 Hz, 1H), 2.04 (d, *J* = 12.5 Hz, 1H), 1.68
10 (qd, *J* = 11.8, 4.1 Hz, 1H), 1.46 (qd, *J* = 11.8, 4.1 Hz, 1H).

11
12
13
14
15
16
17
18
19
20 ***N*-[2-[(3*R*)-3-Amino-1-piperidyl]-2-oxo-ethyl]-4-cyano-*N*-(2-methylindazol-5-
21 yl)benzenesulfonamide (22).**

22
23
24 Prepared in a manner analogous to compound **21a** using sulfonamide **19** and **S11**, to afford the title
25 compound as a white powder, TFA salt (18 mg, 25%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.32 (m,
26 2H), 8.17 (s, 2H), 8.13–7.99 (m, 3H), 7.83 (t, *J* = 8.6 Hz, 2H), 7.59–7.45 (m, 2H), 7.01 (dd, *J* = 9.0,
27 2.1 Hz, 1H), 4.81–4.68 (m, 2H), 4.63 (d, *J* = 16.9 Hz, 1H), 4.14 (s, 3H), 3.67 (m, 1H), 3.15–3.05 (m,
28 1H), 3.02–2.83 (m, 1H), 1.93 (s, 1H), 1.80–1.28 (m, 2H).

29
30
31
32
33
34
35
36 **1-Acetyl-*N*-[2-(4-amino-1-piperidyl)-2-oxo-ethyl]-*N*-[4-(3,5-dimethylpyrazol-1-yl)-3-methoxy-
37 phenyl]indoline-5-sulfonamide (23).**

38
39
40 Prepared in a manner analogous to compound **21b** using sulfonamide **20** and **S12**, to afford the title
41 compound as a white powder (34 mg, 52%). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.55 (s, 1H), 8.20
42 (d, *J* = 9.0 Hz, 1H), 7.60–7.49 (m, 2H), 7.21 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.07 (d, *J* = 2.2 Hz, 1H), 6.90
43 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.05–5.98 (m, 1H), 4.73 (d, *J* = 16.2 Hz, 1H), 4.62 (d, *J* = 16.2 Hz, 1H),
44 (dd, *J* = 8.4, 2.2 Hz, 1H), 4.51 (d, *J* = 13.9 Hz, 1H), 4.20 (t, *J* = 8.7 Hz, 3H), 3.71 (s, 3H), 3.71 (s, 1H), 3.39 (td, *J* = 7.3, 3.6 Hz,
45 1H), 3.24 (t, *J* = 8.7 Hz, 3H), 2.82–2.64 (m, 1H), 2.27 (s, 3H), 2.22 (d, *J* = 1.6 Hz, 3H), 2.12 (d, *J* =
46 11.9 Hz, 1H), 2.06 (s, 3H), 1.73–1.55 (m, 1H), 1.54–1.37 (m, 1H).

47
48
49
50
51
52
53
54
55
56 **Preparation of compounds 29–32**

Route to glycine core***tert*-Butyl *N*-[1-[2-(4-cyanoanilino)acetyl]-4-piperidyl]carbamate (25).**

To a solution of *N*-(4-cyanophenyl)glycine (1 g, 5.7 mmol), COMU (2.95 g, 6.8 mmol) and 4-[(*tert*-butoxycarbonyl)amino]piperidine (1.36 g, 6.8 mmol) in DMF (10 mL) was added *N,N*-diisopropylethylamine (1.93 mL, 11.35 mmol). After 10 min a white precipitate formed. Stirring was continued for 30 min, then water (50 mL) was added. The precipitate was filtered, washed with water (3 × 10 mL) and dried to afford the title compound (2.02 g, 99%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.65–7.50 (m, 2H), 6.86–6.73 (m, 2H), 6.62 (t, *J* = 5.1 Hz, 1H), 6.21 (d, *J* = 9.1 Hz, 1H), 4.10 (d, *J* = 5.1 Hz, 2H), 3.66–3.48 (m, 1H), 3.56–3.35 (m, 3H), 3.42–3.29 (m, 1H), 1.82–1.67 (m, 4H), 1.40 (s, 9H). f: (High pH) *t*_R 1.07 min, *m/z* 357.2 [M–H][–], 100% purity.

***tert*-Butyl *N*-[[1-[2-(4-cyanoanilino)acetyl]-4-piperidyl]methyl]carbamate (26).**

To a solution of *N*-(4-cyanophenyl)glycine (0.5 g, 2.8 mmol), COMU (730 mg, 3.4 mmol) in DMF (10 mL) was added *N,N*-diisopropylethylamine (0.97 mL, 5.7 mmol). After 10 min a white precipitate formed. Stirring was continued for 30 min, and then water (50 mL) was added. The resulting white precipitate was filtered, washed with water (3 × 10 mL) and dried to afford the title compound (1.04 g, 98%) as a white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.51–7.40 (m, 2H), 6.90 (t, *J* = 5.9 Hz, 1H), 6.82–6.68 (m, 2H), 6.63 (t, *J* = 5.1 Hz, 1H), 4.34 (d, *J* = 13.3 Hz, 1H), 3.98 (t, *J* = 5.1 Hz, 2H), 3.88 (d, *J* = 13.3 Hz, 1H), 2.97 (t, *J* = 12.8 Hz, 1H), 2.87–2.78 (m, 2H), 2.58 (d, *J* = 12.8 Hz, 1H), 1.64 (t, *J* = 10.8 Hz, 4H), 1.38 (s, 9H), 1.20–0.79 (m, 2H). LC-MS: (High pH) *t*_R 1.07 min, *m/z* 372.3 [M–H][–], 100% purity.

***tert*-Butyl *N*-[[1-[2-(4-cyanoanilino)acetyl]-4-fluoro-4-piperidyl]methyl]carbamate (27).**

Prepared in a manner analogous to compound **25** using **24** and *tert*-butyl *N*-[(4-fluoropiperidin-4-yl)methyl]carbamate to afford the title compound (356 mg, 87%) as a pink powder. This product was used in the next step without further purification.

***tert*-Butyl 7-[2-(4-cyanoanilino)acetyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate (28).**

To a solution of *N*-(4-cyanophenyl)glycine (370 mg, 2.1 mmol), COMU (1.08 g, 2.5 mmol) and *tert*-butyl-2,7-diazaspiro[3.5]nonane-2-carboxylate (500 mg, 2.2 mmol) in DMF (5 mL) at 0 °C was added *N,N*-diisopropylethylamine (0.71 mL, 4.2 mmol). After 10 min a white precipitate formed. Stirring was continued for 30 min, then water (50 mL) was added. The precipitate was filtered, washed with water (3 × 10 mL) and recrystallized from ethyl acetate (30 mL) to afford the title compound (598 mg, 74%) as an off-white powder. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.50–7.41 (m, 2H), 6.82–6.70 (m, 2H), 6.65 (t, *J* = 5.0 Hz, 1H), 3.99 (d, *J* = 5.0 Hz, 2H), 3.59 (br s, 4H), 3.40 (br s, 4H), 1.71 (t, *J* = 5.5 Hz, 2H), 1.61 (t, *J* = 5.5 Hz, 2H), 1.38 (s, 9H). LC-MS: (High pH) *t*_R 1.11 min, *m/z* 383.3 [M–H][–], 98% purity.

4-[[2-(4-Amino-1-piperidyl)-2-oxo-ethyl]-(*p*-tolylmethyl)amino]benzotrile (29a).

A stirred suspension of *tert*-butyl *N*-[1-[2-(4-cyanoanilino)acetyl]-4-piperidyl]carbamate (50 mg, 0.14 mmol), 4-methylbenzyl bromide (31 mg, 0.17 mmol) and potassium carbonate (48 mg, 0.35 mmol) in DMF (500 μL) was heated to 80°C for 1 h, then concentrated to dryness. 4 M HCl in dioxane (1 mL) was added and the reaction mixture stirred for 1 h, then concentrated to dryness and purified by preparative HPLC (high pH) to afford the title compound (17 mg, 34%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.53–7.32 (m, 2H), 7.16 (s, 4H), 6.76–6.62 (m, 2H), 4.63 (s, 2H), 4.56 (d, *J* = 8.4 Hz, 1H), 4.48 (d, *J* = 4.5 Hz, 2H), 4.03 (d, *J* = 14.1 Hz, 1H), 3.47–3.33 (m, 1H), 3.30–3.14 (m, 1H), 2.79 (t, *J* = 12.3 Hz, 1H), 2.32 (s, 3H), 2.12–2.05 (m, 2H), 1.65 (qd, *J* = 12.3, 4.2 Hz, 1H), 1.51 (qd, *J* = 12.3, 4.2 Hz, 1H).

4-[(*N*-[2-(4-Amino-1-piperidyl)-2-oxo-ethyl]-4-cyano-anilino)methyl]-2-fluoro-benzotrile (29b).

Prepared in a manner analogous to compound **29a** using 4-cyano-3-fluorobenzyl bromide to afford the title compound (17 mg, 15%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.74 (dd, *J* = 8.2, 6.7 Hz, 1H), 7.51–7.44 (m, 2H), 7.42–7.31 (m, 2H), 6.72–6.60 (m, 2H), 4.78 (s, 2H), 4.58 (d, *J* = 9.1 Hz, 2H), 4.06 (d, *J* = 14.3 Hz, 1H), 3.51–3.34 (m, 2H), 3.30–3.17 (m, 1H), 2.81 (t, *J* = 13.2 Hz, 1H), 2.10 (t, *J* = 13.2 Hz, 2H), 1.65 (qd, *J* = 12.3, 4.2 Hz, 1H), 1.51 (qd, *J* = 12.3, 4.2 Hz, 1H).

1
2
3 **4-[[2-(4-Amino-1-piperidyl)-2-oxo-ethyl]-[(3-fluoro-4-methoxy-**
4
5 **phenyl)methyl]amino]benzonitrile (29c).**
6
7

8 Prepared in a manner analogous to compound **29a** using 3-fluoro-4-methoxybenzyl bromide to afford
9 the title compound (17 mg, 31%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.55–7.36
10 (m, 2H), 7.15–6.94 (m, 4H), 6.78–6.64 (m, 2H), 4.61 (s, 3H), 4.51 (d, *J* = 6.0 Hz, 2H), 4.04 (d, *J* =
11 14.2 Hz, 1H), 3.86 (s, 3H), 3.23 (t, *J* = 12.8 Hz, 1H), 2.80 (t, *J* = 12.8 Hz, 1H), 2.09 (t, *J* = 11.9 Hz,
12 2H), 1.65 (m, 1H), 1.50 (m, 1H). ¹⁹F NMR (300 MHz, Methanol-*d*₄) δ -135.7. ¹³C NMR (75 MHz,
13 Chloroform-*d*) δ 168.6, 154.0 (d, *J* = 245 Hz), 153.2, 148.9, 133.8, 131.0 (d, *J* = 5.4 Hz), 122.5 (d, *J*
14 = 3.6 Hz), 120.7, 115.8 (d, *J* = 18.8 Hz), 114.5, 113.4, 99.1, 86.4, 58.2, 56.1, 54.7, 49.2, 43.4, 33.0.
15 HRMS (ESI) *m/z* [M+H]⁺ calcd for C₂₂H₂₆O₂N₄F: 397.2034. Found: 397.2022.
16
17

18 **4-[[2-(4-Amino-1-piperidyl)-2-oxo-ethyl]-benzyl-amino]benzonitrile (29d).**
19
20
21

22 Prepared in a manner analogous to **29a** using benzyl bromide to afford the title compound (12 mg,
23 25%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.51–7.39 (m, 2H), 7.41–7.21 (m, 5H),
24 6.77–6.65 (m, 2H), 4.68 (s, 2H), 4.64–4.41 (m, 3H), 4.03 (d, *J* = 14.0 Hz, 1H), 3.43–3.27 (m, 1H),
25 3.21 (t, *J* = 13.0 Hz, 1H), 2.79 (t, *J* = 13.0 Hz, 1H), 2.17–1.95 (m, 2H), 1.70–1.55 (m, 1H), 1.58–1.39
26 (m, 1H).
27

28 **4-[[2-(4-Amino-1-piperidyl)-2-oxo-ethyl]-[(1-methylindazol-5-yl)methyl]amino]benzonitrile**
29 **(29e).**
30
31

32 Prepared in a manner analogous to **29a** using 5-(bromomethyl)-1-methyl-1H-indazole hydrobromide
33 to afford the title compound (13 mg, 21%) as a white powder. ¹H NMR (300 MHz, Methanol-*d*₄) δ
34 7.93 (d, *J* = 0.9 Hz, 1H), 7.65 (dd, *J* = 1.7, 0.9 Hz, 1H), 7.56 (dt, *J* = 8.6, 0.9 Hz, 1H), 7.50–7.35 (m,
35 3H), 6.80–6.69 (m, 2H), 4.79 (s, 2H), 4.61 (s, 1H), 4.54 (d, *J* = 6.0 Hz, 2H), 4.06 (s, 3H), 4.01 (s, 1H),
36 3.46–3.28 (m, 1H), 3.22 (t, *J* = 13.0 Hz, 1H), 2.80 (q, *J* = 12.1, 11.7 Hz, 1H), 2.13–2.01 (m, 2H),
37 1.71–1.45 (m, 2H).
38

39 **4-[[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-(*p*-tolylmethyl)amino]benzonitrile (30a).**
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Prepared in a manner analogous to **30b** (see below), affording the title compound (25 mg, 47%) as a
4
5 white powder, bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.50–7.38 (m, 2H), 7.16 (s,
6
7 4H), 6.78–6.66 (m, 2H), 4.62 (s, 2H), 4.55 (d, *J* = 13.7 Hz, 1H), 4.45 (s, 2H), 3.96 (d, *J* = 14.0 Hz,
8
9 1H), 3.15 (q, *J* = 11.1, 9.4 Hz, 1H), 2.95–2.84 (m, 2H), 2.72 (t, *J* = 13.1 Hz, 1H), 2.32 (s, 3H), 1.97
10
11 (tt, *J* = 7.3, 3.8 Hz, 1H), 1.86 (d, *J* = 13.4 Hz, 2H), 1.40–1.15 (m, 2H). ¹³C NMR (75 MHz, Methanol-
12
13 *d*₄) δ 168.9, 153.7, 138.1, 135.7, 134.3, 130.5, 127.8, 121.3, 113.7, 99.0, 56.4, 52.9, 45.4, 42.9, 35.6,
14
15 30.1, 21.1. HRMS (ESI) *m/z* [M+H]⁺ calcd for C₂₃H₂₉ON₄: 377.2336. Found: 377.2320.

16
17
18 **4-[[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-[(4-chlorophenyl)methyl]amino]benzonitrile**
19
20 **(30b).**

21
22 A stirred suspension of tert-butyl N-[[1-[2-(4-cyanoanilino)acetyl]-4-piperidyl]methyl]carbamate (50.
23
24 mg, 0.14 mmol), 4-chlorobenzyl bromide (43 mg, 0.21 mmol) and potassium carbonate (48 mg, 0.35
25
26 mmol) in DMF (0.5 mL) was heated to 80 °C for 1 h, then purified by HPLC (high pH). 4 M HCl in
27
28 dioxane (1 mL) was added and the reaction mixture concentrated to dryness to afford the title
29
30 compound (27 mg, 37%) as a white powder, bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄)
31
32 δ 7.42–7.29 (m, 2H), 7.35–7.13 (m, 6H), 6.58 (dd, *J* = 9.8, 2.8 Hz, 2H), 4.78 (d, *J* = 1.1 Hz, 2H), 4.55
33
34 (d, *J* = 7.0 Hz, 3H), 3.87 (d, *J* = 14.1 Hz, 1H), 3.14–2.98 (m, 1H), 2.79 (dd, *J* = 7.2, 2.9 Hz, 2H), 1.76
35
36 (s, 2H), 1.43–1.01 (m, 3H).

37
38
39
40 **4-[[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-[(4-fluorophenyl)methyl]amino]benzonitrile**
41
42 **(30c).**

43
44 Prepared in a manner analogous to **30b** using 4-fluorobenzyl bromide to afford the title compound (13
45
46 mg, 21%) as a white powder, bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.40–7.28
47
48 (m, 2H), 7.28–7.14 (m, 2H), 7.04–6.89 (m, 2H), 6.66–6.54 (m, 2H), 4.55 (s, 2H), 4.44 (d, *J* = 13.2 Hz,
49
50 1H), 4.37 (s, 2H), 3.88 (d, *J* = 13.9 Hz, 1H), 3.70–3.54 (m, 1H), 3.06 (t, *J* = 13.0 Hz, 1H), 2.90–2.71
51
52 (m, 2H), 2.62 (td, *J* = 13.0, 2.7 Hz, 1H), 1.97–1.66 (m, 3H), 1.35 (d, *J* = 13.0 Hz, 1H), 1.30–1.00 (m,
53
54 2H).

55
56
57
58 **3-[(N-[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-4-cyano-anilino)methyl]benzamide (30d).**
59
60

1
2
3 Prepared in a manner analogous to **30b** using 3-(chloromethyl)benzamide to afford the title compound
4 (14 mg, 22%) as a white powder, bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.76–
5 7.62 (m, 2H), 7.49–7.29 (m, 4H), 6.67–6.55 (m, 2H), 4.63 (d, *J* = 1.8 Hz, 2H), 4.42 (s, 3H), 3.89 (d, *J*
6 = 13.8 Hz, 1H), 3.21 (t, *J* = 1.8 Hz, 1H), 3.06 (t, *J* = 12.9 Hz, 1H), 2.84–2.74 (m, 2H), 2.71–2.53 (m,
7 1H), 1.87 (tt, *J* = 7.3, 3.8 Hz, 2H), 1.76 (m, 3H), 1.30–1.00 (m, 2H).
8
9
10
11
12

13
14 **4-[(*N*-[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-4-cyano-anilino)methyl]benzamide (30e).**
15

16 Prepared in a manner analogous to **30b** using 4-(chloromethyl)benzamide to afford the title compound
17 (12 mg, 18%) as a white powder, bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄) δ 7.81–
18 7.70 (m, 2H), 7.39–7.33 (m, 2H), 7.33–7.25 (m, 2H), 6.59 (d, *J* = 9.0 Hz, 2H), 4.64 (s, 2H), 4.49–4.42
19 (m, 1H), 4.40 (s, 2H), 3.88 (d, *J* = 14.1 Hz, 1H), 3.68–3.53 (m, 4H), 3.06 (t, *J* = 12.7 Hz, 1H), 2.78
20 (dd, *J* = 6.9, 4.1 Hz, 2H), 2.62 (t, *J* = 12.6 Hz, 1H), 2.00–1.62 (m, 2H), 1.44–1.00 (m, 1H).
21
22
23
24
25
26

27
28 **4-[[2-[4-(Aminomethyl)-1-piperidyl]-2-oxo-ethyl]-[(3-fluoro-4-methoxy-
29 phenyl)methyl]amino]benzonitrile (30f).**
30
31

32 Prepared in a manner analogous to **30b** using 3-fluoro-4-methoxybenzyl bromide to afford the title
33 compound (23 mg, 40%) as a white powder, bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄)
34 δ 7.42–7.29 (m, 2H), 7.03–6.89 (m, 3H), 6.67–6.55 (m, 2H), 4.50 (s, 2H), 4.43 (d, *J* = 14.7 Hz, 1H),
35 4.36 (s, 2H), 3.89 (d, *J* = 14.7 Hz, 1H), 3.76 (s, 3H), 3.06 (t, *J* = 12.8 Hz, 1H), 2.79 (dd, *J* = 6.8, 3.7
36 Hz, 2H), 2.62 (t, *J* = 12.8 Hz, 1H), 1.96–1.53 (m, 3H), 1.26–1.04 (m, 2H). ¹³C NMR (75 MHz,
37 MeOD) δ 169.0, 153.9 (d, *J* = 247 Hz), 153.5, 148.4, 134.1, 131.9 (d, *J* = 5.4 Hz), 124.2 (d, *J* = 3.6
38 Hz), 121.0, 115.9, 114.5 (d, *J* = 18.9 Hz), 114.2, 99.7, 56.8, 55.9, 53.1, 45.2, 42.9, 35.6, 30.1. HRMS
39 (ESI) *m/z* [M+H]⁺ calcd for C₂₃H₂₈O₂N₄F: 411.2191. Found: 411.2175.
40
41
42
43
44
45
46
47
48

49
50 **4-[[2-[4-(Aminomethyl)-4-fluoro-1-piperidyl]-2-oxo-ethyl]-[(3-fluoro-4-methoxy-
51 phenyl)methyl]amino]benzonitrile (31)**
52
53

54 Prepared in a manner analogous to **30b** using acid **27** as a starting material to afford the title
55 compound as a white powder (9 mg, 17%), bis-hydrochloride salt. ¹H NMR (300 MHz, Methanol-*d*₄)
56
57
58
59
60

1
2
3 δ 7.45 (dd, $J = 8.9, 4.0$ Hz, 2H), 7.22–6.93 (m, 2H), 6.83–6.62 (m, 2H), 4.68–4.34 (m, 4H), 3.88 (s,
4 3H), 3.86–3.54 (m, 2H), 3.67 (s, 1H), 3.45 (t, $J = 12.5$ Hz, 1H), 3.28 (d, $J = 3.0$ Hz, 1H), 3.22 (s, 1H),
5 3.05 (t, $J = 12.8$ Hz, 1H), 2.17–1.57 (m, 8H). ^{19}F NMR (282 MHz, Methanol- d_4) δ -136.50 (m), -
6 169.24 (dddd, $J = 38.0, 29.5, 20.2, 10.0$ Hz).

11
12 **4-[[2-(2,7-Diazaspiro[3.5]nonan-7-yl)-2-oxo-ethyl]-[(3-fluoro-4-methoxy-**
13 **phenyl)methyl]amino]benzotrile (32).**

14
15
16 A stirred suspension of **28** (330 mg, 0.64 mmol), 4-(bromomethyl)-2-fluoro-1-methoxybenzene (282
17 mg, 1.3 mmol) and potassium carbonate (222 mg, 1.6 mmol) in DMF (3 mL) was heated to 120 °C by
18 microwave irradiation for 0.5 h. The reaction mixture was adsorbed onto silica then purified by
19 automated column chromatography (0 to 70% EtOAc in isohexane). 4M HCl/dioxane (1 mL) was
20 added and the mixture stirred for 1 hour, then concentrated to dryness. The resulting residue was
21 purified by preparative HPLC (high pH) to afford the title compound (33 mg, 12%) as a white
22 powder. $^1\text{H}\{^{19}\text{F}\}$ NMR (300 MHz, Methanol- d_4) δ ^1H NMR (300 MHz, Methanol- d_4) δ 8.58 (s, 1H),
23 7.51–7.39 (m, 2H), 7.13–6.99 (m, 3H), 6.76–6.65 (m, 2H), 4.60 (s, 2H), 4.46 (s, 2H), 3.86 (s, 3H),
24 3.57 (br m, 2H), 3.50 (br m, 3H), 3.36 (s, 1H), 1.93 (br m, 2H), 1.86 (br m, 2H). ^{19}F NMR (282 MHz,
25 Methanol- d_4) δ -136.57 (m). ^{13}C NMR (75 MHz, MeOD) δ 168.8, 153.8 (d, $J_{\text{C,F}} = 247$ Hz), 153.3,
26 148.2, 134.2, 131.9 (d, $J_{\text{C,F}} = 5.4$ Hz), 123.8 (d, $J_{\text{C,F}} = 3.6$ Hz), 121.3, 115.5 (d, $J_{\text{C,F}} = 18.9$ Hz),
27 115.0, 113.8, 99.2, 86.4, 56.8, 56.3, 52.9, 49.9, 42.4, 40.0, 38.2, 35.3. HRMS (ESI) m/z $[\text{M}+\text{H}]^+$ calcd
28 for $\text{C}_{24}\text{H}_{28}\text{O}_2\text{N}_4\text{F}$: 423.2191. Found: 423.2181.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 *LSD1 enzymatic assay*

45
46 Assays were performed in Corning® 384 well low flange white flat bottom polystyrene (#3574)
47 microplates in a 10 μL reaction volume consisting of 50 mM TrisHCl, 50 mM NaCl, 1mM DTT,
48 0.01% Tween-20, 1% DMSO with or without compound in a 10-point, 3-fold dilution series, 0.2 μM
49 Histone H3(1–21)K4(Me1) biotin peptide substrate (AnaSpec Inc., Fremont, CA) and 1 nM LSD1
50 (Enzo Life Sciences, New York, NY). The reaction was allowed to proceed for 30 min at 25 °C before
51 stopping the reaction with the addition of 0.3 mM tranlylcypromine in LANCE detection buffer and
52
53
54
55
56
57
58
59
60

1
2
3 quantifying the level of demethylated peptide by the addition of 1 nM Europium- α -unmodified H3K4
4 antibody and 25 nM ULight Streptavidin (both from Perkin Elmer, Waltham, MA), also in LANCE
5 detection buffer. Following a further 60 min incubation period the TR-FRET signal was read on a
6
7 PHERAstar FS plate reader (BMG LabTech, Ortenberg, DE) with excitation at 340 nm and emission
8
9 at 665 nm.
10
11

12 13 *SPR binding assay*

14
15
16 Direct binding between compounds and LSD1 was assessed by SPR using Biacore T200, S200 and
17 S51 instruments (GE Healthcare, Uppsala, Sweden). LSD1 was immobilized to CM5 or CM7 chips
18 using amine coupling. Interaction experiments were performed at 15 °C in 10 mM HEPES, pH 7.4,
19 150 mM NaCl, 1% DMSO, 0.05% Tween, at a flow rate of 30 mL/min. Compounds were diluted in
20 the buffer and injected for 15 – 25 s at increasing concentrations over the prepared surfaces.
21
22 Sensorgrams were double-referenced by subtracting signals from untreated reference channel and
23 responses from blank injections. Affinities were derived by either dose-response analysis of steady
24 state responses or regressions analysis of whole sensorgrams (1:1 interaction model including a term
25 for mass transport limitation) using the T200 evaluation software 3.0 (GE Healthcare).
26
27
28
29
30
31
32
33
34

35 36 *Cell lines*

37
38 THP1 and MV4-11 cell lines were obtained from DSMZ (Braunschweig, Germany). All cell lines
39 were cultured in RPMI supplemented with 10% FBS and 2mM L-glutamine (Sigma Aldrich, Poole,
40 UK).
41
42
43
44

45 46 *Clonogenic assays*

47
48 Clonogenic assays of human leukaemic cell lines were performed in methylcellulose medium (H4320,
49 Stem Cell Technologies, Vancouver, BC) with no supplemental growth factors. Cells were seeded at
50 2.5×10^3 and colonies enumerated after 7 days in culture.
51
52
53
54

55 56 *CD86 and apoptosis assays*

1
2
3 For CD86 assays, leukaemic cell lines were incubated in culture medium containing compounds or
4 DMSO (vehicle control) for 48 h at a density of 1×10^5 /ml. Cells were pelleted, resuspended in 100 ml
5 SM buffer (Phenol red free RPMI, 5 mM EDTA and 2% BSA (Sigma Aldrich)) containing 0.25ul
6 CD86-PerCP EF710 (Clone IT2.2, eBioscience, Thermo Fisher Scientific) and incubated at 4 °C for
7 10 mins. Cells were washed, resuspended in SM buffer and analyzed by flow cytometry. To
8 determine the effects of compounds on apoptosis, leukaemic cell lines were incubated with 10 μ M
9 compound or vehicle for 4 days. Apoptosis was assessed using a BD Pharmingen PerCP-Cy5.5
10 Annexin V/7-AAD Kit (BD Biosciences), according to manufacturer's instructions. All FACS
11 analyses were performed using either an LSR Model II (BD Biosciences, Oxford, UK) or NovoCyte
12 (ACEA Biosciences) flow cytometer or FACSArray Bioanalyser (BD Biosciences).
13
14
15
16
17
18
19
20
21
22
23

24 *Glide docking*

25
26
27 Docking into the active site of LSD1 was carried out for each of the synthesized ligands. Molecules
28 were docked in their predicted charged form at pH 7.4. Compounds were docked into the crystal
29 structure of tetrahydrofolate bound to LSD1 (PDB code 4KUM) with all structural waters removed.
30
31 Docking was performed in Glide 6.7, in standard precision mode and without further minimisation.
32
33 Glidescore was used for conformation scoring of each ligand.
34
35
36
37
38
39
40

41 **ASSOCIATED CONTENT**

42 **Supporting Information**

43
44 The supporting information is available free of charge via the Internet at <http://pubs.acs.org>. SPR
45 sensorgrams for selected compounds; LC-MS methods and solvent gradients; preparative HPLC
46 instrument and solvent gradients; summary of purity data; molecular formula strings.
47
48
49
50

51 **Abbreviations**

52
53 AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid;
54
55 COMU, 1-Cyano-2-ethoxy-2-oxoethylidenaminoxy)dimethylamino-morpholino-carbenium
56
57 hexafluorophosphate; DIPEA, N,N-diisopropylethylamine; GFI, growth factor independence; K_d ,
58
59
60

1
2
3 dissociation constant; LSD1, lysine specific demethylase 1; MeCN, acetonitrile; MLL, mixed lineage
4 leukemia; SPR, surface plasmon resonance; TR-FRET, time resolved fluorescence resonance energy
5 transfer.
6
7

14 AUTHOR INFORMATION

16 Corresponding author

17 *Telephone: +44 (0)161-446-8079. Email: allan.jordan@cruk.manchester.ac.uk.

20 Notes

21
22 Tim Somervaille has ongoing research collaborations with Oryzon Genomics and consults for Imago
23 Biosciences. The other authors declare no competing financial interest.

26 Acknowledgments

27
28 This work was supported by Cancer Research UK (Grants C5759/A12328, C480/A11411,
29 C5759/A17098 and C5759/A02901). Additional support was provided to DPM by the Society of
30 Chemical Industry through a Messel Scholarship. HRMS spectra were generated by Gareth Smith,
31 School of Chemistry, University of Manchester, Manchester, UK. Assistance with Glide docking was
32 kindly provided by Bohdan Waszkowycz. In vitro pharmacokinetic and hERG data was provided by
33 Cyprotex Discovery, Macclesfield, UK. JChem for Excel was used for structure property prediction
34 and calculation, and general data handling (JChem for Excel, version 15.6.2900, 2008–2015,
35 ChemAxon (<http://www.chemaxon.com>)). Ligand interaction diagrams in Figure 5 was generated
36 within Maestro (Schrödinger, LLC, New York, NY), and images of protein-ligand complexes within
37 the PyMOL Molecular Graphics System, Version 1.7.6.2. (Schrödinger, LLC, New York, NY).

48 References

- 49
50
51 1. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y.
52 Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **2004**, *119*, 941-
53 953.
54
55
56
57
58
59
60

- 1
2
3 2. Amente, S.; Lania, L.; Majello, B. The histone LSD1 demethylase in stemness and cancer
4 transcription programs. *Biochim. Biophys. Acta, Gene Regul. Mech.* **2013**, *1829*, 981-986.
- 5
6
7 3. Shi, Y.-J.; Matson, C.; Lan, F.; Iwase, S.; Baba, T.; Shi, Y. Regulation of LSD1 histone
8 demethylase activity by its associated factors. *Mol. Cell* **2005**, *19*, 857-864.
- 9
10
11 4. Laurent, B.; Ruitu, L.; Murn, J.; Hempel, K.; Ferrao, R.; Xiang, Y.; Liu, S.; Garcia,
12 Benjamin A.; Wu, H.; Wu, F.; Steen, H.; Shi, Y. A specific LSD1/KDM1A isoform regulates
13 neuronal differentiation through H3K9 demethylation. *Mol. Cell* **2015**, *57*, 957-970.
- 14
15
16
17 5. Yang, M.; Gocke, C. B.; Luo, X.; Borek, D.; Tomchick, D. R.; Machius, M.; Otwinowski, Z.;
18 Yu, H. Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1
19 histone demethylase. *Mol. Cell* **2006**, *23*, 377-387.
- 20
21
22
23 6. Saleque, S.; Kim, J.; Rooke, H. M.; Orkin, S. H. Epigenetic regulation of hematopoietic
24 differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. *Mol. Cell* **2007**,
25 *27*, 562-572.
- 26
27
28
29 7. Ishikawa, Y.; Gamo, K.; Yabuki, M.; Takegi, S.; Toyoshima, K.; Kazuhide, N.; Nakayama,
30 A.; Morimoto, M.; Miyashita, H.; Dairiki, R.; Hikichi, Y.; Tomita, N.; Tomita, D.; Imamura, S.;
31 Iwatani, M.; Kamada, Y.; Matsumoto, S.; Hara, R.; Nomura, T.; Tsuchida, T.; Kazuhide, N. A novel
32 LSD1 inhibitor T-3775440 disrupts GFI1B containing complex leading to transdifferentiation and
33 impaired growth of AML cells. *Mol. Cancer Ther.* **2017**, *16*, 273-284
- 34
35
36
37 8. Velinder, M.; Singer, J.; Bareyan, D.; Meznarich, J.; Tracy, C. M.; Fulcher, J. M.; McClellan,
38 D.; Lucente, H.; Franklin, S.; Sharma, S.; Engel, M. E. GFI1 functions in transcriptional control and
39 cell fate determination require SNAG domain methylation to recruit LSD1. *Biochem. J.* **2016**, *473*,
40 3355.
- 41
42
43
44 9. Velinder, M. E.; Singer, J.; Meznarich, J.; Theisen, E. R.; Fulcher, J.; Tracy, C.; Franklin, S.;
45 Sharma, S.; Engel, M. E. GFI1 snag domain methylation directs LSD1 recruitment to control
46 transcription and cell fate determination in hematopoiesis. *Blood* **2015**, *126*, 46.
- 47
48
49
50 10. Harris, W. J.; Huang, X.; Lynch, J. T.; Spencer, G. J.; Hitchin, J. R.; Li, Y.; Ciceri, F.; Blaser,
51 J. G.; Greystoke, B. F.; Jordan, A. M.; Miller, C. J.; Ogilvie, D. J.; Somervaille, T. C. P. The histone
52
53
54
55
56
57
58
59
60

1
2
3 demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell*
4
5 **2012**, *21*, 473-487.

6
7 11. Döhner, H.; Estey, E. H.; Amadori, S.; Appelbaum, F. R.; Büchner, T.; Burnett, A. K.;
8
9 Dombret, H.; Fenaux, P.; Grimwade, D.; Larson, R. A.; Lo-Coco, F.; Naoe, T.; Niederwieser, D.;
10
11 Ossenkoppele, G. J.; Sanz, M. A.; Sierra, J.; Tallman, M. S.; Löwenberg, B.; Bloomfield, C. D.
12
13 Diagnosis and management of acute myeloid leukemia in adults: recommendations from an
14
15 international expert panel, on behalf of the European LeukemiaNet. *Blood* **2010**, *115*, 453-474.

16
17 12. Mohammad, H. P.; Smitheman, K. N.; Kamat, C. D.; Soong, D.; Federowicz, K. E.;
18
19 Van Aller, G. S.; Schneck, J. L.; Carson, J. D.; Liu, Y.; Butticello, M.; Bonnette, W. G.; Gorman, S.
20
21 A.; Degenhardt, Y.; Bai, Y.; McCabe, M. T.; Pappalardi, M. B.; Kasparec, J.; Tian, X.; McNulty, K.
22
23 C.; Rouse, M.; McDevitt, P.; Ho, T.; Crouthamel, M.; Hart, T. K.; Concha, N. O.; McHugh, C. F.;
24
25 Miller, W. H.; Dhanak, D.; Tummino, P. J.; Carpenter, C. L.; Johnson, N. W.; Hann, C. L.; Kruger, R.
26
27 G. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC.
28
29 *Cancer Cell* **2015**, *28*, 57-69.

30
31 13. Hill, J. M.; Quenelle, D. C.; Cardin, R. D.; Vogel, J. L.; Clement, C.; Bravo, F. J.; Foster, T.
32
33 P.; Bosch-Marce, M.; Raja, P.; Lee, J. S.; Bernstein, D. I.; Krause, P. R.; Knipe, D. M.; Kristie, T. M.
34
35 Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic
36
37 suppression of viral genomes. *Sci. Transl. Med.* **2014**, *6*, 265ra169

38
39 14. Liang, Y.; Quenelle, D.; Vogel, J. L.; Mascaro, C.; Ortega, A.; Kristie, T. M. A novel
40
41 selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and
42
43 reactivation from latency. *mBio* **2013**, *4*, e00558-12.

44
45 15. Buesa, C.; Mascaró, C.; Rotllant, D.; Griñan-Ferré, C.; Pallàs, M.; Maes, T. The dual
46
47 LSD1/MAO-B inhibitor ORY2001 prevents the development of the memory deficit in samp8 mice
48
49 through induction of neuronal plasticity and reduction of neuroinflammation. *Alzheimer's Dementia*
50
51 **2015**, *11*, 905.

52
53 16. Maes, T.; Arjol, C. B. Selective LSD1 and dual LSD1/MAO-B inhibitors for modulating
54
55 diseases associated with alterations in protein conformation. U.S. Pat. Appl. 20160081947, 2016.
56
57
58
59
60


- 1
2
3 17. Guibourt, N.; Munoz, A. O.; Laria, J. C.-P. Phenylcyclopropylamine derivatives and their
4 medical use. U.S. Pat. 8,993,808, 2015
5
6
7 18. Somervaille, T.; Salamero, O.; Montesinos, P.; Willekens, C.; Perez Simon, J. A.; Pigneux,
8 A.; Recher, C.; Popat, R.; Molinero, C.; Mascaro, C.; Maes, T.; Bosch, F. Safety, pharmacokinetics
9 (PK), pharmacodynamics (PD) and preliminary activity in acute leukemia of ORY-1001, a first-in-
10 class inhibitor of lysine-specific histone demethylase 1A (LSD1/KDM1A): initial results from a first-
11 in-human phase 1 study. *Blood* **2016**, *128*, 4060.
12
13
14
15
16
17 19. Johnson, N. W.; Kasparec, J.; Rouse, M. B.; Tian, X.; Miller, W. H.; Suarez, D.
18 Cyclopropylamines as LSD1 inhibitors. U.S. Pat. 9346840, 2016.
19
20
21 20. Yongchun, P.; Han, W.; Cao, G; Frietze, W.; Zhongjiang, J.; Sharief, V.; Zhou, J.; Li, Q. Salts of
22 an LSD1 inhibitor. U.S. Pat. Appl. 201700440101, 2017.
23
24
25 21. Schenk, T.; Chen, W. C.; Gollner, S.; Howell, L.; Jin, L.; Hebestreit, K.; Klein, H.-U.;
26 Popescu, A. C.; Burnett, A.; Mills, K.; Casero, R. A.; Marton, L.; Woster, P.; Minden, M. D.; Dugas,
27 M.; Wang, J. C. Y.; Dick, J. E.; Muller-Tidow, C.; Petrie, K.; Zelent, A. Inhibition of the LSD1
28 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid
29 leukemia. *Nat. Med.* **2012**, *18*, 605-611.
30
31
32
33
34
35 22. Liu, X.; Stubbs, M.; Ye, M.; Collins, R.; Favata, M.; Yang, G.; Diamond, M.; Dostalík, V.;
36 Lo, Y.; He, C.; Wu, L.; Combs, A.; Yao, W.; Hollis, G.; Huber, R.; Scherle, P.; Ruggeri, B.; Liu, P.;
37 Lee, S. H. Abstract 4702: Combination of BET inhibitor INCB054329 and LSD1 inhibitor
38 INCB059872 is synergistic for the treatment of AML in vitro and in vivo. *Cancer Res.* **2016**, *76*,
39 4702.
40
41
42
43
44
45 23. Vasilatos, S. N.; Katz, T. A.; Oesterreich, S.; Wan, Y.; Davidson, N. E.; Huang, Y. Crosstalk
46 between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic
47 efficacy of HDAC inhibitors in human breast cancer cells. *Carcinogenesis* **2013**, *34*, 1196-1207.
48
49
50
51 24. Mould, D. P.; McGonagle, A. E.; Wiseman, D. H.; Williams, E. L.; Jordan, A. M. Reversible
52 inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress
53 to date. *Med. Res. Rev.* **2015**, *35*, 586-618.
54
55
56
57
58
59
60

- 1
2
3 25. Hitchin, J. R.; Blagg, J.; Burke, R.; Burns, S.; Cockerill, M. J.; Fairweather, E. E.; Hutton, C.;
4
5 Jordan, A. M.; McAndrew, C.; Mirza, A.; Mould, D.; Thomson, G. J.; Waddell, I.; Ogilvie, D. J.
6
7 Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments.
8
9 *MedChemComm* **2013**, *4*, 1513-1522.
- 10
11 26. Johnson, N. W. The identification of GSK2879552, a mechanism based irreversible inhibitor
12
13 of the histone lysine demethylase LSD1. Presented at XXIV EFMC International Symposium on
14
15 Medicinal Chemistry, Manchester, UK, August 28 - September 1, 2016.
- 16
17 27. Chen, Y., K.; Kanouni, T.; Nie, Z.; Stafford, J. A.; Veal, J. M.; Sung, L. M. Inhibitors of
18
19 lysine specific demethylase-1. W.O. Pat. Appl. 2016004105, 2016.
- 20
21 28. Chen, Y. K.; Kanouni, T.; Kaldor, S. W.; Stafford, J. A.; Veal, J. M. Inhibitors of lysine
22
23 specific demethylase-1. W.O. Pat. Appl. 2015089192, 2015
- 24
25 29. Chen, Y. K.; Kanouni, T.; Nie, Z.; Stafford, J. A.; Veal, J. M.; Sung, L. M. Inhibitors of
26
27 lysine specific demethylase-1. W.O. Pat. Appl. 2016003917, 2016.
- 28
29 30. Liangxing, W.; Courter, J. R.; Chunhong, H.; Jingwei, L.; Liang, L.; Yaping, S.; Xiaozhao,
30
31 W.; Wenqing, Y.; Zhang, C.; Jincong, Z. Imidazopyrazines as LSD1 inhibitors. U.S. Pat. Appl.
32
33 20160009720, 2016.
- 34
35 31. Liangxing, W.; Konkol, L. C.; Lajkiewicz, N.; Liang, L.; Meizhong, X.; Wenqing, Y.; Zhang,
36
37 C.; Chunhong He. Imidazopyridines and imidazopyrazines as LSD1 inhibitors. U.S. Pat. Appl.
38
39 20160009712, 2016.
- 40
41 32. Liangxing, W.; Xiaozhao, W.; Wenqing, Y.; Zhang, C. Triazolopyridines and
42
43 triazolopyrazines as LSD1 Inhibitors. U.S. Pat. Appl. 20160009711, 2016.
- 44
45 33. Sartori, L.; Mercurio, C.; Amigoni, F.; Cappa, A.; Fagá, G.; Fattori, R.; Legnaghi, E.;
46
47 Ciossani, G.; Mattevi, A.; Meroni, G.; Moretti, L.; Cecatiello, V.; Pasqualato, S.; Romussi, A.; Thaler,
48
49 F.; Trifiró, P.; Villa, M.; Vultaggio, S.; Botrugno, O. A.; Dessanti, P.; Minucci, S.; Zagarrí, E.;
50
51 Caretoni, D.; Iuzzolino, L.; Varasi, M.; Vianello, P. Thieno[3,2-b]pyrrole-5-carboxamides as new
52
53 reversible inhibitors of histone lysine demethylase KDM1A/LSD1. Part 1: high throughput screening
54
55 and preliminary exploration. *J. Med. Chem.* **2017**, *60*, 1673-1692.
- 56
57
58
59
60

- 1
2
3 34. Vianello, P.; Sartori, L.; Amigoni, F.; Cappa, A.; Fagá, G.; Fattori, R.; Legnaghi, E.; Ciossani,
4 G.; Mattevi, A.; Meroni, G.; Moretti, L.; Cecatiello, V.; Pasqualato, S.; Romussi, A.; Thaler, F.;
5 Trifiró, P.; Botrugno, O. A.; Villa, M.; Dessanti, P.; Minucci, S.; Vultaggio, S.; Zagarrí, E.; Varasi,
6 M.; Mercurio, C. Thieno[3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine
7 demethylase KDM1A/LSD1. Part 2: structure based drug design and structure-activity relationship. *J.*
8 *Med. Chem.* **2017**, *60*, 1693-1715.
- 9
10
11
12
13
14
15 35. Speranzini, V.; Rotili, D.; Ciossani, G.; Pilotto, S.; Marrocco, B.; Forgione, M.; Lucidi, A.;
16 Forneris, F.; Mehdipour, P.; Velankar, S.; Mai, A.; Mattevi, A. Polymyxins and quinazolines are
17 LSD1/KDM1A inhibitors with unusual structural features. *Sci. Adv.* **2016**, *2* (9), e1601017.
- 18
19
20
21 36. Song, Y.; Xue, X.; Wu, X.; Wang, R.; Xing, Y.; Yan, W.; Zhou, Y.; Qian, C.-N.; Zhang, Y.;
22 Xu, Y. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new ROR γ inverse
23 agonists: Virtual screening, structure-based optimization, and biological evaluation. *Eur. J. Med.*
24 *Chem.* **2016**, *116*, 13-26.
- 25
26
27
28
29 37. Lynch, J. T.; Cockerill, M. J.; Hitchin, J. R.; Wiseman, D. H.; Somerville, T. C. P. CD86
30 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone
31 demethylase lysine-specific demethylase 1. *Anal. Biochem.* **2013**, *442*, 104-106.
- 32
33
34
35 38. Wu, F.; Zhou, C.; Yao, Y.; Wei, L.; Feng, Z.; Deng, L.; Song, Y. 3-(Piperidin-4-
36 ylmethoxy)pyridine containing compounds are potent inhibitors of lysine specific demethylase 1. *J.*
37 *Med. Chem.* **2016**, *59*, 253-263.
- 38
39
40
41 39. Cheeseright, T. J.; Mackey, M. D.; Melville, J. L.; Vinter, J. G. FieldScreen: virtual screening
42 using molecular fields. Application to the DUD data set. *J. Chem. Inf. Model* **2008**, *48*, 2108-2117.
- 43
44
45 40. Park, B. K.; Boobis, A.; Clarke, S.; Goldring, C. E. P.; Jones, D.; Kenna, J. G.; Lambert, C.;
46 Laverty, H. G.; Naisbitt, D. J.; Nelson, S.; Nicoll-Griffith, D. A.; Obach, R. S.; Routledge, P.; Smith,
47 D. A.; Tweedie, D. J.; Vermeulen, N.; Williams, D. P.; Wilson, I. D.; Baillie, T. A. Managing the
48 challenge of chemically reactive metabolites in drug development. *Nat. Rev. Drug Discovery* **2011**,
49 *10*, 292-306.
- 50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 41. Luka, Z.; Pakhomova, S.; Loukachevitch, L. V.; Calcutt, M. W.; Newcomer, M. E.; Wagner,
4 C. Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate.
5 *Protein Sci.* **2014**, *23*, 993-998.
6
7
8
9 42. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.;
10 Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide:
11 a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking
12 accuracy. *J. Med. Chem.* **2004**, *47*, 1739-1749.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE OF CONTENTS GRAPHIC







Figure 1. Compound **1** and examples from several series disclosed by QuanticeL Pharmaceuticals in WO2015/089192 (**2-6**).²⁵

77x33mm (600 x 600 DPI)



24
25
26
27

Figure 2. Development and characterization of compound **10b**. A: Biochemical assay; B: Surrogate cellular biomarker assay; C: Surface plasmon resonance sensorgram of the interaction between LSD1 and **10b** in two-fold dilution series (highest concentration indicated in the graph).

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

422x211mm (96 x 96 DPI)




Figure 3. Structure of compound **12** with biochemical and SPR sensorgram indicating the highest tested concentration. $K_d = 9.5 \mu\text{M}$. K_d value was determined by SPR at 15 °C as the average of two experimental series (typically 10 concentrations).

41x15mm (600 x 600 DPI)





Figure 4. Cresset Torch alignment and structures of compound **1** (left) and **16g** (right). Similarity score 0.712. Blue field points (spheres) highlight energy minima for a positively charged probe, red for a negative probe. Yellow spheres represent an attractive van der Waals minimum for a neutral probe and brown spheres represent hydrophobic regions. Oxygen atoms are shown in red, nitrogen in blue. The similarity score is based on the likeness of the field points in terms of their magnitude and position. A score of greater than 0.7 is considered a 'good' score.


1068x696mm (96 x 96 DPI)



Scheme 1: Synthesis of compounds 10a–b^a

^aReagents and conditions: (i) 3,5-dimethylpyrazole, K₂CO₃, DMF, 80 °C, 16 h, 99%; (ii) Zn, ammonium formate, MeOH, 40 °C, 16 h, 78%; (iii) appropriate sulfonyl chloride, pyridine, 100 °C, 1 h, 41–70%.


29x4mm (600 x 600 DPI)



Scheme 2: Synthesis of compounds 12 and 16a-m^a


^aReagents and conditions: (i) 4-acetamidobenzenesulfonyl chloride, DMAP, MeCN, μ W, 100 °C, 1 h, 37% (ii) 4-methylphenylsulfonyl, pyridine, MeCN, RT, 12 h, 89%; (iii) tert-butyl bromoacetate, K_2CO_3 , DMF, 1 h, 96%; (iv) TFA, DCM, 1 h, 98%; (v) amine, DIPEA, COMU, DMF, then 4M HCl/dioxane if Boc deprotection required, RT, 12–68%.

85x45mm (600 x 600 DPI)



Scheme 4: Synthesis of compounds 29a-e, 30a-f, 31 and 32^a ^aReagents and conditions: i) Boc-protected diamine, DIPEA, COMU, DMF, rt, 1 h, 67 – 99%; ii) substituted benzyl-bromide, K₂CO₃, DMF, 80°C, 1 h, then 4 M HCl/dioxane, rt, 1 h, 6–58%

103x55mm (300 x 300 DPI)



Scheme 3: Synthesis of compounds 21a–b, 22 and 23^a Reagents and conditions: (i) 1-acetylimidazole-5-sulfonyl chloride, pyridine, MeCN, RT, 12 h, 84%; (ii) (**21a**) tert-butyl N-[(3R)-1-(2-chloroacetyl)-3-piperidyl]carbamate, K₂CO₃, cat. KI, DMF, 80 °C, 3 h; then TFA, 1 h, RT, 42%; (**21b**) tert-butyl N-[1-(2-chloroacetyl)-4-piperidyl]carbamate, K₂CO₃, 80 °C, 6 h, then 4M HCl/dioxane, 70%; (iii) 2-methyl-2H-indazole-5-amine, pyridine, MeCN, RT, 12 h, 54%; (iv) tert-butyl N-[(3R)-1-(2-chloroacetyl)-3-piperidyl]carbamate, K₂CO₃, cat. KI, DMF, 80 °C, 3 h; then TFA, 1 h, RT, 25%; (v) 1-acetylimidazole-5-sulfonyl chloride, pyridine, MeCN, RT, 12 h, 54%; (vi) tert-butyl N-[1-(2-chloroacetyl)-4-piperidyl]carbamate, K₂CO₃, DMF, 80 °C, 6 h, then 4M HCl/dioxane, 1 h RT, 52%.

109x71mm (300 x 300 DPI)




Figure 5. Top: Predicted binding mode of compound **30f** in the LSD1 active site (4KUM). Visualized using Maestro. Bottom: Protein-ligand interaction diagram with key hydrogen bond interactions highlighted (pink arrows).

490x752mm (96 x 96 DPI)




Figure 6. CD86 cell assay results for compounds **1**, **30f** and **32**.

80x50mm (300 x 300 DPI)




Figure 7. Top: Colony formation assay for THP-1 and MV4-11 cells dosed with 10 μ M of compounds 1 and 32 for 7 days. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, statistical significance calculated using a one-way ANOVA with Dunnett's tests between vehicle treated and compound dosed cells. Bottom: representative images of colonies.

251x461mm (300 x 300 DPI)




Figure 8. Annexin V-perCP EF710/7AAD double staining experiments results with THP-1 cell dosed with vehicle, or 10 μ M **1** or **32** for 4 days in liquid culture. Early apoptotic cells = Annexin V^{pos}7-AAD^{neg}; Apoptotic cells = Annexin V^{pos}7-AAD^{pos}. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, statistical significance calculated using one-way ANOVA analysis with Dunnett's tests.

60x35mm (300 x 300 DPI)